sept13_nwp_50939 22/08/2013 13:01 Page 1 A WORK & TURN COVER Focus on REPRODUCTION European Society of Human Reproduction and Embryology // SEPTEMBER 2013 // Another record-breaking congress l Fertility and female obesity l Latest on European IVF monitoring l ESHRE journals hit the high spots sept13_nwp_50939 22/08/2013 13:02 Page 2 sept13_nwp_50939 22/08/2013 13:02 Page 3 EXECUTIVE COMMITTEE Chairman Juha Tapanainen (FI Chairman Elect Kersti Lundin (SE) Members Helle Bendtsen (DK) Carlos Calhaz-Jorge (PT) Roy Farquharson (GB) Anis Feki (CH) Georg Griesinger (DE) Grigoris Grimbizis (GR) Nils Lambalk (NL) Cristina Magli (IT) Tatjana Motrenko (ME) Jacques De Mouzon (FR) Andres Salumets (EE) Petra De Sutter (BE) Ex-officio members Anna Veiga (ES) (Past Chairman) Timur Gurgan (TR) (SIG Sub-committee) FOCUS ON REPRODUCTION EDITORIAL COMMITTEE Bruno Van den Eede Hans Evers Roy Farquharson Joep Geraedts Luca Gianaroli Juha Tapanainen Anna Veiga Simon Brown (Editor) Focus on Reproduction is published by The European Society of Human Reproduction and Embryology Meerstraat 60 Grimbergen, Belgium www.eshre.eu All rights reserved. The opinions expressed in this magazine are those of the authors and/or persons interviewed and do not necessarily reflect the views of ESHRE. SEPTEMBER 2013 CONTENTS Focus on Reproduction September 2013 Focus on REPRODUCTION l Chairman’s introduction As the new Chairman of ESHRE let me first thank all members for trusting me with this challenging job. ESHRE is the ‘reproduction flagship’ of Europe, with members drawn from physicians to scientists, from psychologists to ethicists, from nurses to lab technicians. This gives the Society strength and values which make it unique in reproduction. All the signs indicate that ESHRE is in good condition, both scientifically and socially. This is the result of decades of steady progress, to which our members and officers have all contributed. I would particularly like to thank Anna Veiga and Luca Gianaroli for their efforts over recent years. Anna will continue as Past Chairman while Luca has stepped down after holding different positions for 14 years. Other retiring members of the Executive Committee have all had special tasks in the team and ESHRE is very grateful for their contributions. New friendships as well as working together make voluntary Society work rewarding. As before, the new Executive Committee consists of members from different disciplines in reproduction, and from two new countries, Estonia and Montenegro. Although ESHRE is a big society, which sometimes slows down decision-making, it is not a static society. So, besides its proven and safe core functions, I strongly believe that the Society should look to new forms of activity, which may involve risk and may not always turn out as hoped for. And to this extent there are three subjects which need attention: the development of e-learning programmes; a facelift for our traditional workshops; and, perhaps most importantly, new ways of publishing our journals. All will prove challenges for the Executive Committee. The Annual Meeting was once again a huge success. Almost 1600 abstracts were submitted and the number of registered participants in London exceeded 10,000. Thanks to a well-planned scientific programme, and expert organisation from Bruno and his Central Office colleagues, the event was well received. Everyone involved deserves a big thank-you. The future of ESHRE, of course, relies on the involvement of young people. We have already taken some initiatives to attract younger colleagues, but all new ideas and thoughts are welcome. The opinions of members are important, and I will do my best to ensure that all views are equally heard. Alone one cannot do much, but co-operation can work wonders. Juha Tapanainen ESHRE Chairman 2013-20015 NEWS FEATURES 4 10 13 14 16 18 19 20 26 Felice Petraglia in profile A record-breaking annual meeting Annual assembly of members minutes New impact factors for ESHRE jounals IVF monitoring 2010 A view on aneuploidy screening Paramedical Group From the PGD Consortium From the Special Interest Groups The editor of Human Reproduction Update talks to FoR 28 Obesity and female fertility Jose Bellver on the ovarian, endometrial and embryonic effects of obesity 33 Robert Edwards Final tributes from Luca Gianaroli and Basil Tarlatzis 3 sept13_nwp_50939 22/08/2013 13:03 Page 4 ANNUAL MEETING 2013 Budget babies . . . safer babies at a record-breaking annual meeting The local organisers of this year’s annual meeting in London had optimistically planned for an attendance of 10,000, and in the event that was just the number who took part, a total registration of 10,007, which broke all previous records and put the ESHRE congress squarely at the top of world events in reproductive medicine. In 1985, when ESHRE organised its first annual meeting, 650 attended; who could have foreseen such spectacular growth in less than 30 years? For now as never before had so many people attended an ESHRE event, and never before had the sun shone on London so gloriously for four uninterrupted days. 4 As ever, this was a congress rich in its diversity and authority. Reports from 223 studies (selected from 1589 originally submitted abstracts) were presented during 71 invited and oral communication sessions. And it was fitting that, in this year of the death of ESHRE’s founder, the opening keynote lecture was given in honour of Sir Robert Edwards. Victor Gomel, who last year in Istanbul had been awarded honorary membership of ESHRE, described Edwards as a giant in science but as Victor Gomel presents the opening keynote lecture in commemoration of Sir Robert Edwards. Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:03 Page 5 someone whose humility and kindness never let him ignore his fellow man. Gomel, like so many in this huge opening audience, was astounded that honours from his native country came so late in life to Edwards. Following Gomel onto the opening session stage was the Swedish (though Australian native) embryologist Aisling Ahlström, whose Human Reproduction keynote lecture was based on her group’s study of the morphological parameters for predicting blastocyst viability. Her published paper had had the highest number of full-text downloads during the first six months of publication in 2011, and, in its emphasis on embryo selection in IVF, stamped the congress with a theme which was evident throughout the following three days. Ahlström’s study was a retrospective analysis of 1117 fresh single blastocyst transfers and their live birth outcome related to each of three morphological parameters: degree of blastocoele expansion and appearance of both the trophectoderm and the inner cell mass. Results showed that all three parameters had a significant effect on live birth but, with adjustment for known confounders, the number and cohesion of trophectoderm cells was the only statistically significant independent predictor of live birth. Embryo viability was also the aim of a highscoring proof-of-principle study reported by Dagan Wells from the NIHR Biomedical Research Centre in Oxford, UK. His presentation described the validation of next generation sequencing in cells and blastocysts with known chromosomal and genetic defects - with what Wells described as ‘an unprecedented insight into the biology of embryos’. Genomic sequencing, he said, could potentially identify chromosomal, genetic and mitochondrial abnormalities from a single test within about 16 hours (and so without the need for freezing while awaiting results). The final stage of the study had been the delivery of healthy babies to two women in the USA who had previously had miscarriages and whose later embryos had been assessed by genomic sequencing. One of the potential benefits of the technique, Wells added, is lower cost. Current genetic tests, he said, ‘are relatively high and beyond the reach of many patients. Next generation sequencing is a way which could make chromosome testing more widely available to a greater number of patients.’ This was not the only study in London to describe genomic sequencing for embryo selection. A study reported in the same session by Jian Li from BGI Shenzhen in China presented an evaluation of what he called ‘massively parallel sequencing’ for the detection of chromosomal Focus on Reproduction September 2013 Honorary membership of ESHRE was awarded to the Finnish embryologist Outi Hovatta (by former ESHRE Chairman Anna Veiga) and to the UK gynaecologist Allan Templeton (by fellow Scot and local organiser Roy Farquharson). abnormalities. Li, also describing the technique as ‘low cost’ and powerful, reported the outcome of testing 150 trophectoderm samples from blastocysts, with a high detection rate and 14 live births already recorded. Low cost was at the heart of another proof-ofprinciple study from the Genk Institute for Fertility Technology in Belgium, which claimed that, with a simple two-tube Alka-Seltzer-fired incubator, a Dagan Wells cycle of IVF could be performed for around €200. described validation studies ‘This simplified lab procedure will undoubtedly of next generation open up a new era in the history of IVF,’ said sequencing for investigator Elke Klerkx. ‘The method not only embryo selection offers affordable and successful access to IVF, but in IVF. will make effective treatment techniques available to a much larger part of the world’s infertile population.’ The study was led by Willem Ombelet, coordinator of ESHRE’s Task Force for Developing Countries and Infertility, whose aim is to make the diagnosis and treatment of infertility available and accessible to poor-resourced countries. The incubator system consists of two glass tubes, the first of which serves as the generator of CO2 from citric acid and sodium bicarbonate. This brings into equilibrium the culture medium in the second tube. Low-cost results so far, said Klerkx, were comparable with those from the hi-tech lab. In 23 of 35 cycles assessed (66%) the top quality embryo originated from the simplified culture system. In this low-cost group the implantation rate was 34.8% (8/23), with an ongoing pregnancy rate of 30.4% (7/23). Up to May this year, 12 healthy low-cost babies had been born. But if cost was one recurring theme of this year's Elke Klerkx congress, another was safety, and this year’s award presented proof of for the top oral presentation in clinical science was principle that an unanimously awarded to a huge linkage study IVF cycle for performed at the Institute of Child Health in developing countries can be London whose results showed emphatically that the children born after ART have no greater risk performed for around €200 per of cancer than children conceived spontaneously. cycle. ‘This is reassuring news for couples considering 5 B INNER sept13_nwp_50939 22/08/2013 13:03 Page 6 assisted conception, their subsequent children, fertility specialists and for the wider public health,’ said the investigator Carrie Williams reporting the results. This was a large population-based linkage study between the Human Fertilisation & Embryology Authority (HFEA) and the UK’s National Registry of Childhood Tumours (NRCT). The HFEA records of all 106,381 children born after ART in the UK from 1992 to 2008 were linked to NRCT records to calculate the number of children who subsequently developed cancer. Once the databases were linked, cancer rates in the ART cohort were compared with population rates, whilst stratifying for potential mediating factors. The average duration of follow up was 6.6 years. Results showed that there was no overall increased risk of cancer in ART children born throughout the 17-year study period. Overall, 108 cancers were identified in the ART children, which was comparable with the 109.7 cases which would have been expected from general population figures. A similar though smaller study reported in London produced comparable findings. The CoNARTaS cohort study from three Nordic countries also found that children and young adults born after IVF had no overall increased risk of cancer when compared with children in the general population. The study group comprised 92,809 children born after IVF between 1982 and 2007 (61,547 singletons and 31,262 multiples), and a matched control group from the general population four times greater in number. Data on perinatal outcomes and cancer were obtained by 6 B OUTER linkage to national registries. A cancer diagnosis occurred in 143 children born after IVF (19/1000) and in 626 (18/1000) children in the control group. The most common cancer diagnosis was leukaemia, which occurred in 6/1000 children born after IVF and in 5/1000 in the control group. Another cohort study, this time from the Netherlands, found that women who give birth to multiple babies following IVF Carrie Williams treatment are at a higher risk of breast cancer (HR presented an 1.44) than those giving birth to singletons or who award-winning remain childless. The investigators from the Omega linkage study emphatically study group said the explanation may not be the ruling out any multiple pregnancy per se but a maternal trait excess cancer risk related to a higher implantation potential and to in children breast cancer itself. Remarkably, only multiple conceived by ART. pregnancies conceived after the complete implantation of all transferred embryos were associated with an increased breast cancer risk (HR 1.86), whereas multiple pregnancies conceived after incomplete implantation were not (HR 1.31). This finding, said investigator Els Groenveld, supports the hypothesis of a link between high embryo implantation potential and breast cancer risk. That link, she added, could be maternal serum concentrations of vascular endothelial growth factor (VEGF), a known protein involved in breast cancer progression and which her group in Amsterdam has recently found associated with improved embryo implantation potential. Meanwhile, a new study based on a 20-year follow-up of one of the world’s largest study cohorts suggests that male exposure to several factors in utero and in early life may lead to reduced semen parameters in adulthood - and potentially to a decline in male fertility. The study found that adverse fetal growth, exposure to maternal smoking, and a lower childhood growth Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:03 Page 7 Annual assembly ratifies new Executive Committee for 2013-2015 ESHRE’s new Executive Committee comprises, left to right, Anis Feki (CH), Georg Griesinger (DE), Juha Tapanainen (FI, the new Chairman), Carlos Calhaz Jorge (PT), Andres Salumets (EE), Roy Farquharson (GB), Cristina Magli (IT), Nils Lambalk (NL), Anna Veiga (ES, Past Chairman), Jacques de Mouzon (FR), Kersti Lundin (SE, Chairman Elect), Petra De Sutter (BE), Tatjana Motrenko (ME), Helle Bendtsen (DK, Paramedical Group Chairman), Grigoris Grimbizis (GR) and Timur Gurgan (TR, SIG Committee). trajectory were all associated with a subsequent decline in testicular function, with around one in six of the men tested having sperm parameters below the ‘normal’ WHO threshold. When these findings were correlated with the earlier fetal growth assessments, being consistently small in utero was associated with a significantly greater chance of having a sperm assessment within the lowest quartile; men with good intrauterine growth were less likely to be in this lowest quartile of sperm production in adulthood. Being exposed to their mothers’ smoking was also associated with lower sperm production. New introductions to the lab One of the most entertaining hot-topic invited sessions of the congress was the debate on the introduction of new innovations without clinical trial. Speaking in favour of the motion, Simon Fishel not unreasonably invoked much of IVF’s chequered history to his cause, noting in particular the rapid acceptance of ICSI into Focus on Reproduction September 2013 Els Groeneveld: A common trait in women with high implantation potential and raised breast cancer risk? everyday practice without the luxury of a clinical trial. ICSI notwithstanding, however, one suspected that lurking in the wings of this debate was time-lapse imaging, whose introduction has been slipped into many IVF labs without the benefit - as yet - of any RCT results. Sure enough, Fishels’s opponent in the debate, Sigrid Sterckx from the Bioethics Institute of Ghent, Belgium, quickly brought the time-lapse case forward to centre-stage, while noting that in ART ‘RCTs seem to be the exception rather than the rule’. And one reason for this paucity of trials, Sterckx lamented, is the ever lengthening arm of commercialisation in the field of ART. And she too - as had the embryologist Jacques Cohen in an RBM Online editorial just weeks before questioned the granting of ‘time lapse’ patents to Stanford University for what seems no more than a law of nature in the development of embryos. ‘Doubts must exist as to the validity of these claims,’ she said. For the record the split of opinion before the debate was roughly 50-50, 7 sept13_nwp_50939 22/08/2013 13:03 Page 8 For the second year, the congress programme was downloadable as an app for smart phones and tablets. More than 4000 copies were downloaded from the App Store and Google, suggesting that almost half this year’s participants were paper-free. which, to the surprise of many, remained the difference of opinion at the end. This same basic question on the validity and safety of new introductions in IVF was first raised more than three years ago by the bioethicist Wybo Dondorp in an opening keynote lecture at the 2010 annual meeting in Rome. Then, the issue in question was the introduction of vitrification for the cryopreservation of oocytes. Now, with the technique clearly established (even in the USA and without substantial trials) the more generic consideration of new techniques (when to introduce, how to define the experimental phase, how to test validity) has come before ESHRE’s Executive Committee and thence to a working committee of two Special Interest Groups More than 400 serious and not-so-serious runners registered for Monday evening’s 5 km charity run along the Thames bankside. The event, through entry fees and generous sponsorship, raised more than €1500 for ESHRE’s partner patient organisation Fertility Europe. 8 (Ethics & Law, and Safety & Quality in ART). The outcome of their considerations was presented as a position paper in London with two major proposals: first, the addition of a new category of ‘innovative treatment’ to lie between the ‘experimental’ and ‘established’ phases; and second, a sequential four-criteria tool for the consistent assessment of new treatments and technologies based on efficacy, safety, procedure and effectiveness. The transition between experimental and established would thus depend on how the technique scored in each of these four criteria. ‘This is a conceptual framework, not a decisive tool,’ said Veerle Provoost on behalf of the SIG Ethics & Law. ‘Its purpose is to raise discussion about treatments.’ Innovative treatment, she added, could only be reached when ‘experimental’ procedures have demonstrated proof of principle (efficacy) and reassurance in terms of safety, when data have been reported in peer-reviewed journals, and when patients have been offered clear information. ‘Established’ treatment might only be reached when multicentre data is published in peer-reviewed journals, on which basis it is regarded as a safe and effective therapy, and when procedures are performed according to a standard protocol. Another report to emerge from an ESHRE working group (comprising the Task Force for Cross-border Reproductive Care and IVF Monitoring Consortium) was on the contentious subject of egg donation, currently one of the most frequent reasons why couples travel abroad for treatment. The study, which surveyed (by questionnaire) 1423 egg donors at 60 clinics in 11 European countries to discover their Guido Pennings: ‘The fact motivations, found that the that a person receives majority of donors are keen to compensation or money help infertile couples for does not mean that she is motivated by that money.’ altruistic reasons, but that a large proportion also expect a personal benefit, usually financial. The extent to which financial compensation was important seemed dependent on country and on donor age. The younger the donor, the more likely would money be the motive. The study did, however, find that altruism was the principal motive overall. ‘The fact that a person receives compensation or money does not mean that she is motivated by that money,’ said Guido Pennings presenting the results on behalf of the Task Force. High levels of pure donor altruism were found in Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:03 Page 9 Award winners from ESHRE 2013. From left to right: l Jie Li (CN) for the Clinical Science Award for poster presentation (Embryonic human chorionic gonadotropin (hCG) in spent culture medium may tell embryo viability in IVF-ET program: a multi-center study) l Jacky Boivin (GB) representing Hetty Ockuysen et al (NL) for the Nurses Award (Can a self-administered coping intervention reduce anxiety in women awaiting the outcome of IVF treatment - a randomised controlled trial) l Souraya Jaroudi (GB) for the Fertility Society of Australia Exchange Award (Assessment of telomere DNA length in human oocytes and cleavage stage embryos: impact on aneuploidy risk and implantation potential) l Paola Scaruffi (IT) for the Basic Science Award for oral presentation (DNA profiling of culture medium as a novel, non-invasive tool for embryo assessment) l Bart Desmet (BE) for the ART Laboratory Award (Evaluation of the frozen embryo stock and destination of the frozen embryos in a large scale cryopreservation program) l Pénélope Troude (FR) for the Basic Science Award for poster presentation (Cumulative parenthood rates in 6,507 couples treated by in vitro fertilization) l Carrie Williams (GB) for the Clinical Science Award for oral presentation (Cancer risk in children born after assisted conception) Belgium (86%), Finland (89%) and France (100%), and high levels of purely financial motivation in Greece (39%), Russia (47%) and Ukraine (28%). - a reflection, no doubt, of the growing importance of ART in these two countries. More than 2000 took part in the precongress courses on Sunday, also with record rating scores (4.2 out of 5 for quality). Remarkably, more than As ever, the scientific programme was promoted to 560 registered for the precongress course the press by ESHRE’s Central Office, with organised by the SIG Reproductive Endocrinology widespread media coverage. Notably, the proofon efficacy and safety in ovarian stimulation for of-principle study from Belgium on low cost IVF ART. for poor-resource countries attracted the widest ESHRE’s survey of delegate response to the media coverage, with reports popping up in all overall meeting found ratings for scientific quality corners of the world. and educational value of around 4 (with 5 the top For the 10,007 delegates on site in London this rating), while overall organisation and social was yet again a well received meeting, with high events also scored high. Sixty per cent of those satisfaction scores. Most participants - not questioned said they would expect to attend surprisingly - came from the UK (753), but next year’s event in Munich, whose second Congress attendance there was also strong attendance from Italy announcement was published in London. Rome 2010 9,204 (484) and Spain (410). However, the Precongress courses are already planned, and Stockholm 2011 8,361 presence of non-European countries was this Istanbul 2012 the outline of the main invited programme in 9,066 year much in evidence, with 458 place. Will ESHRE’s congress records London 2013 10,007 registrations from India and 300 from China continue to fall in Bavaria? Focus on Reproduction September 2013 9 C INNER sept13_nwp_50939 22/08/2013 13:03 Page 10 ANNUAL ASSEMBLY OF MEMBERS // ANNUAL MEETING 2013 // ESHRE’s Annual Assembly of Members took place at the ExCeL centre, London, on 9th July 2013 at 18.00. The minutes of the meeting are recorded below. Matters arising and their approval will take place at next year’s Annual Assembly in Munich. 1. Minutes of the last meeting held in Istanbul - The minutes of the 2012 Annual Assembly of Members (AAM), having been circulated to all members in Focus on Reproduction (September 2012), were approved. 2. There were no matters arising. 3. Membership of the Society - Membership of the Society now stands at 5823, a small decline on last year’s number (6223); almost 70% of members come from Europe. The top European membership countries are UK (464 members), Italy (312), Germany (280), Netherlands (272), Belgium (260) and Spain (256). North and South America represent 9% of total membership. - Disciplines most prominently represented are embryology (1943 members) and reproductive endocrinology (1734), but there is strong membership presence in andrology, early pregnancy, safety & quality, and reproductive surgery. ‘ESHRE is not a society of clinicians,’ the Chairman noted; around 50% of the membership is now drawn from basic science, laboratory disciplines and nursing. 4. Society activities Training - Campus events and precongress courses continue to dominate the training programme, with events in 2013 comparable in number (30) with those of 2012 (32). Events of the past two years represent a slight but planned reduction from 2010’s peak (of almost 40 total events). The Campus programme in 2013 comprises 15 precongress courses and 14 individually staged stand-alone events. - The Chairman encouraged all members to check the Campus programme on the recently updated ESHRE website for previews of all Campus events (under ‘Calendar’). She also praised the work of colleagues in Central Office for upgrading the look and function of the ESHRE website. SIGs and Task Forces - The Chairman announced the formation of a new Special Interest Group (SIG) on Socio-cultural aspects of (in)fertility. The new SIG, which was formed from a merger of the Task Forces for Cross-border Reproductive Care and Society & Reproduction, will be co-ordinated by Guido Pennings, with Françoise Shenfield and Paul Devroey as deputies. Executive Committee representative will be Jacques de Mouzon. ESHRE certification for reproductive surgeons - ESHRE’s recently introduced Certification for Reproductive Endoscopic Surgeons (ECRES) is the first international certification scheme in the field. The aim is to give gynaecologists with an interest in reproductive surgery an opportunity to validate their skills and establish their status as reproductive surgeons. The programme is now under way, with several members already sitting the first examinations in London. - The Chairman, noting that this programme will run ‘similarly to that for embryo certification’, expressed her thanks to the SIG Reproductive Surgery for making so much progress in this venture in such a short time. Data collection - The Chairman praised the work of the European IVF Monitoring Consortium (EIM) and PGD Consortium. The EIM group, chaired up to the annual meeting by Anna Pia Campus meetings (blue) and precongress courses (red) 2000-2013. 10 C OUTER Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:03 Page 11 Munich from 29th June to 2nd July. The 31st annual meeting in 2015 will be held in Lisbon from 14-17th June. - The next ‘Best of ASRM & ESHRE’ meeting will take place in Cortina d’Ampezzo, Italy, on 27th February-1st March 2014. The Chairman said that the format of the two previous events will be maintained for 2014. Most European countries now report ART data to ESHRE’s IVF Monitoring Consortium. Only two countries, Belarus and Malta, have never submitted any data. The latest report, for 2010, was based on data from 31 countries, of which 18 provided complete cycle-by-cycle data. The EIM estimates that current reports cover 90% of all European ART activity. Ferraretti, is now monitoring more than 500,000 European ART cycles each year, representing a cumulative total of 971,280 babies born since the EIM began its work in 1997. Preliminary data for 2010 presented in London indicate for the first time in recent years a slight divergence in pregnancy rates (per aspiration) between IVF and ICSI at 30.9% for IVF and 28.7% for ICSI. Multiple deliveries continue to decline (from 29.5% in 1997) and have now for the first time fallen below 20% (to 19.2%). Ten countries reported data from IVM cycles, with Russia and France accounting for 68% of these cycles and 46% of deliveries. Almost 5000 cycles of oocyte cryopreservation were reported for 2010, the majority from Italy and Spain; there were 755 deliveries, representing a live birth rate of 15.5% per cycle. - Data from the PGD Consortium were also described as ‘very valuable’. The Chairman said that the latest full report, for 2009, is now ready for publication, with data from 60 centres and 6160 cycles. PGS (in 2009) continued to be the dominant use, though now in moderate decline relative to PGD. Data collection XIII (for 2010) will be published later this year, with data from 64 centres and 6116 cycles. Guidelines - ESHRE’s latest guideline, on the Management of women with endometriosis, was presented during the congress, with publication expected in Human Reproduction later this year. - Other guidelines in progress are on Psychosocial care in infertility and medically assisted reproduction, expected Autumn 2013, Premature ovarian insufficiency, expected Spring 2014, and Recurrent miscarriage, expected Autumn 2014. 5. Future meetings - The Society’s 30th annual meeting in 2014 will be held in Focus on Reproduction September 2013 6. ESHRE journals - Speaking on behalf of the Publications Sub-committee, Hans Evers, editor-in-chief of Human Reproduction, reported the latest impact factors for all three ESHRE journals released just before the congress: Human Reproduction Update from 9.234 in 2011 to 8.847 in 2012; Human Reproduction from 4.475 to 4.670, and MHR from 3.852 to 4.582. ‘The journals are in a healthy situation,’ said Evers, who praised the work of former editors John Collins, André Van Steirteghem and Steve Hillier, noting especially the ‘very steep increase’ achieved by MHR. The three ESHRE journals now occupy the first three positions in the category of Reproductive Biology, while Human Reproduction Update continues to lead the category of Obstetrics and Gynaecology, with Human Reproduction in third place. ‘We are hoping to improve our impact factors each year,’ said Evers, who added that his own appointment as editor-in-chief of Human Reproduction was one of the ‘thrills’ of his career. The most frequently cited article from Human Reproduction in 2012 was the report from the EIM Consortium on IVF data collection for 2007. - Among technology developments for the journals, Evers noted the mobile phone/tablet application with search, browse and e-mail facilities and how its availability had made tablet access to the journals quick and efficient. - Evers reported that submissions to the ESHRE journals continue to rise, with Human Reproduction now attracting more than 2000 manuscripts per year. Reviewing times (to a first decision) are now down to around 30 days, but an ever expanding number of submissions means that the rejection rate (now above 70%) is steadily increasing. Evers reported that he and the publishers are considering ways by which the space occupied by published papers (either by word count or page layout) can be reduced. 7. Paramedical group - Helle Bendtsen, the Chairman of the Paramedical Board, reported that 12% of the total ESHRE membership (689) were from the Paramedical Group. Paramedical members comprise nurses, midwives, lab technicians (the largest group), counsellors and psychologists, and ESHREcertified clinical embryologists up to BSc level. The three most prominently represented countries are Belgium, Denmark and the Netherlands, with more than 60 members from each country. - Among the training events reported was a joint meeting with the SIG SQART on the introduction of new techniques into IVF clinics, which will be followed up later 11 sept13_nwp_50939 22/08/2013 13:03 Page 12 this year with a course on introductions to the IVF lab. The precongress course in Munich next year will be on special patient groups, with an emphasis on trophectoderm biopsy. A further basic training course for paramedics will be held in Paris in May 2014. - As so successfully pioneered for the embryologists (and now for reproductive surgeons), ESHRE and the Paramedical Board are moving ahead with plans for nurse certification. Bendtsen reported that a working group is now in place to plot progress, with an advisory committee also formed to offer clinical and certification expertise. The aim now, said Bendsten, is to develop a framework which defines all the competencies and role requirements for ART nurses in Europe. An outline timeline for the project could see the first certification exams being held in Lisbon in July 2015. 8. Financial report - Past ESHRE Chairman Luca Gianaroli, who has been Chairman of the Finance Sub-committee for the past six years, presented his final report to the AGM summarising the balance sheet (income and expenditure) for 2012 and the budget for 2013. Income in 2012 (€6,865,350) was ahead of expenditure (€5,816,638), leaving a favourable balance of €1,048,712. Both income and the final balance for 2012 were higher than the budget had forecast. - Gianaroli also reviewed financial data from the past ten years showing a positive balance in each year except 2009 (when an increase in expenditure was largely explained by new investment in Campus events). The annual meeting continues to provide the Society’s greatest source of income (71%) and expenditure (55%). A budget similarly constructed to 2012 - to provide a small positive balance has been set for 2013. - The 2012 value of ESHRE’s assets, including stocks and cash balances, increased by more than €800,000 from 2011, and the financial state of the Society was described by Gianaroli as ‘very healthy’. Gianaroli, who was formally thanked for his six years as Chairman of the Finance Sub-committee, noted specifically that ESHRE’s assets had increased during each of his six years as Chairman and were now in total approaching €12 million. ‘I set out to end up with at least the same resources as we started with, and we achieved that and more,’ said Gianaroli. - The financial report for the year ending 31st December 2012 and the budget for 2013 were approved by the members. 9. Executive committee - Nominal changes to the membership of the Executive Committee were unanimously approved by the membership. They were: - Anna Veiga (ES) to step down as Chairman to become immediate Past Chairman, Juha Tapanainen (FI) to become the new Chairman of ESHRE, and Kersti Lundin (SE) the new Chairman Elect. 12 Balance sheet results and budgets 2011-2013: Income (green), expenditure (blue) and balance (pale blue), showing an actual and planned favourable result each year. - Stepping down from the Executive Committee after two two-year terms in office were Miodrag Stojkovic (RS), Anne Maria Suikkari (FI), Etienne Van den Abbeel (BE), Antonis Makrigiannakis (GR), Ursula Eichenlaub (DE) and Milan Macek Jr. (CZ). Stepping down as ex-officio members were Françoise Shenfield (GB) and Luca Gianaroli (IT). All were thanked for their tireless work and commitment. - Continuing for a second two-year term as members of the Executive Committee were Carlos Calhaz Jorge (PT), Jacques de Mouzon (FR), Roy Farquharson (GB), Anis Feki (CH), Nils Lambalk (NL), Cristina Magli (IT) and Helle Bendtsen (DK, PG Chairman). - New members, whose nominations were ratified by the meeting, were Petra De Sutter (BE), Grigoris Grimbizis (GR), Tatjana Motrenko (ME), Andres Salumets (EE), Georg Griesinger (DE), and Timur Gurgan (TR, SIG and TF Coordinator, ex-officio member). 10. Election of honorary members for 2014 - The two nominees proposed by the Executive Committee for honorary membership in 2014 were Sir John Gurdon (international) and Professor Klaus Diedrich (national). Both nominations were ratified by the AAM. 11. Any other business - The new Chairman Juha Tapanainen paid tribute to his predecessor Anna Veiga, describing her as ‘an excellent Chairman’, and to the Executive Committee members ending their terms of office. He also praised the commitment and effort of Luca Gianaroli, whose work with ESHRE went back 14 years and who had finally stepped down from most of his committee responsibilities. ‘Luca has been one of the longest serving members the Society has ever known,’ said the Chairman. The next Annual Assembly will be on 1st July 2014 in Munich at 18.00 pm. Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:03 Page 13 // ESHRE JOURNALS // Three out of three in latest impact factor journal assessment ESHRE titles continue to dominate reproductive biology and Ob/Gyn groups Hans Evers took over in January this year as editor of Human Reproduction. Chris Barratt, new editor of MHR, will continue a policy of high quality manuscripts. For the first time ever ESHRE journals occupy the first very highest quality manuscripts - of both primary data three impact factor positions in the Reproductive and reviews. And that’s how we’ll progress - by actively Biology league table as determined by Thomson seeking manuscripts from leading authors and putting Reuters. The latest figures, released in June just ahead together a series of innovative edgy reviews alongside of the annual meeting in London, are based on journal our original articles.’ citations for 2012. For most investigators - though not l Felice Petraglia, editor-in-chief of Update, echoes the all - impact factors remain the most accessible importance of well commissioned reviews on a broad indicator of journal quality. range of topics - as he explains in more detail on page Human Reproduction’s impact factor climbed from 26 of Focus on Reproduction. 4.475 (for 2011) to 4.67 (for 2012), Update declined slightly Reproductive biology from 9.234 to 8.847, and MHR Title Total cites 5-yr Imp Factor Impact Factor continued its remarkable progress Human Reproduction Update 5685 9.512 8.847 from 3.852 to 4.582. The three journals now dominate the category Human Reproduction 26733 4.596 4.67 of Reproductive Biology and Molecular Hum Reprod 5095 4.009 4.542 occupy three of the first four Fertil Steril 28243 3.96 4.174 positions in Obstetrics and Biol Reprod 22250 4.139 4.027 Gynaecology. Human Reproduction Reproduction 6975 3.512 3.555 Update remains by far the leading Am J Reprod Immunol 3251 2.839 3.317 journal in both categories, with an impact factor almost twice that of Semin Reprod Med 1550 3.864 3.211 any other. Reprod Toxicol 4264 3.94 3.141 Of the other titles in reproductive Placenta 6187 3.179 3.117 medicine, Fertility and Sterility rose to 4.174 and RBM Online to Obstetrics and gynaecology 2.675. All three editors, who took up their Title Total cites 5-yr Imp Factor Impact Factor posts in January this year, praised Human Reproduction Update 5685 9.512 8.947 the work of their predecessors in the Obstet Gynecol 25808 4.908 4.798 continuing development of the Human Reproduction 26733 4.596 4.67 ESHRE journals, while Chris Barratt, 28243 3.96 4.174 the new editor-in-chief of Molecular Fertil Steril Human Reproduction, said: ‘These Gynecol Oncol 18243 3.923 3.929 are very exciting times for the Am J Obstet Gynecol 33759 3.821 3.877 ESHRE journals. MHR in particular BJOG - Int J Obstet Gynecol 12405 3.754 3.76 has seen a consistent rise in impact Ultrasound Obst Gyn 8490 3.84 3.564 factor over the past three years. This Am J Obstet Gynecol 32250 3.708 3.557 is mainly the result of implementing Semin Reprod Med 1550 3.864 3.211 a strict policy of only accepting the Focus on Reproduction September 2013 13 D INNER sept13_nwp_50939 22/08/2013 13:03 Page 14 ANNUAL MEETING // ESHRE IVF MONITORING CONSORTIUM // Europe’s multiple delivery rate finally falls below 20% Reliability of EIM database now rests on a cumulative total of almost one million babies born For the first time, the data generated from European registries have shown a fall in multiple delivery rate to below 20%. Presenting the 14th annual report of ESHRE's European IVF Monitoring (EIM) Outgoing EIM Chairman Anna Pia Ferraretti Consortium, outgoing Chairman Anna Pia Ferraretti said the told the meeting that multiple delivery rate as overall multiple rate in 2010 had fallen to 19.2%, the lowest ever calculated from European regstries and recorded, with a twin rate of 18.5% and triplet rate of 0.7%. reports reached an all-time low of 19.2% in Ferraretti explained that most centres reporting data (56.5%) still 2010. Triplet rate was no higher than 0.7%. transferred two embryos, but the number transferring just one still continues its steady increase - from 12% in 2001 to 26% in 2010. And transfers in a small number of reported since 1997, and almost 1 the number of three and more countries.’ million babies delivered. This, she embryo transfers fell yet again to The annual reports of the EIM, added, is a monumental achievement 17.5%. In Finland and Sweden, which currently include 90% of all and reflects the place of Europe as where SET is agreed policy, the European ART activity, provide the leading region in global IVF. number of singleton transfers was ‘transparency and confidence’ in the This was underlined by David around 70%, with virtually no threetreatments, said Ferraretti, and are Adamson presenting preliminary embryo transfers. ‘These are clear increasingly cited in scientific studies. results (for 2009) from the world trends,’ said Ferraretti, ‘and we’re Their reliability now rests on a report of ICMART. His data showed now only seeing consistent multiple cumulative total of 5,312,318 cycles that Europe (with around 500,000 cycles in 2009) performed 49% of all global ART, with Asia contributing 22% and North America 14%. However, North America once again had the highest delivery rates in 2009, with 34.4% from fresh transfers and 43.4% cumulative. There are now five countries in Europe performing more than 50,000 cycles a year (France, Germany, Italy, Spain, UK). Global trends also showed - for the first time in recent years - a reverse, albeit small, in the proportion of IVF and ICSI treatments carried out. This was also seen in the EIM European data, where (in 2010) the number of For the first time in recent years, the proportion of ICSI treatments (dark blue bars) ICSI cycles performed fell in relation relative to IVF (green bars) has begun to decrease in Europe. to IVF. In countries with a generally 14 D OUTER Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:03 Page 15 World ART activity in 2009: the snapshot from ICMART’s global report David Adamson, Chairman of ICMART and former President of the ASRM, presented ICMART’s preliminary report for 2009. The highlights were: l 1,081,851 cycles reported (an increase of 2.0% on 2008) l An estimated 1.6 million cycles performed worldwide l 243,927 babies born (-6,0%) l An estimated 400,000 babies born worldwide l An estimated ~5 million babies since the beginning l 67.1% ICSI (-2.0%) l 20.3% women >40 (-0.4%) l Mean number of transferred embryos = 1.97 (-0.11) l Delivery rate per aspiration = 19.5 % (-1.3%) l Cumulative delivery rate per aspiration = 25.7% (+1.0%) l Wide differences remain in availability, practice and results low utilisation (such as Denmark and Finland) ICSI accounts for no more than 45% of all ART treatments, but elsewhere (as in Poland, Spain, Switzerland and Italy) ICSI rates are above 80%. Overall in Europe in 2010, ICSI accounted for 65% of treatments and IVF 35% with frozen embryos representing 28% of all transfers. The European data also showed for the first time a difference in pregnancy rates between IVF and ICSI, with IVF recording a 30.9% pregnancy rate per aspiration in 2010, and ICSI a rate of 28.7%. In all annual reports before 2010 outcome rates for both techniques had always been the same. There was, however, much disparity in outcome (and availability) between countries, with pregnancy rates (per aspiration) ranging between 21.5% (Switzerland) and 50.2% (Czech Republic). When stratified for age, the pregnancy rates also emphasised clearly the effect of age from all treatments except egg donation. Earlier this year new by-laws for the EIM Consortium were approved by ESHRE’s Executive Committee. Availability of ART, represented here as cycles per million population, remains patchy in Europe. Global need for ART is considered to be 1500 cycles per million population. Focus on Reproduction September 2013 Among the developments implemented in London was an election process for membership of the EIM Steering Committee, which now comprises Markus Kupka (DE) as Chairman, Anna Pia Ferraretti as Past Chairman, and Karin Erb (DK), Thomas D'Hooghe (BE), José Antonio Castilla Alcala (ES), Carlos Calhaz-Jorge (PT) and Christian De Geyter (BE) as members. Former EIM Chairman Jacques de Mouzon is the ExCo representative. The total Consortium membership for the first time now represents all European countries performing ART. The German gynaecologist Markus Kupka took over as Chairman of the EIM Consortium in London. 15 sept13_nwp_50939 22/08/2013 13:03 Page 16 OPINION // PREIMPLANTATION GENETIC SCREENING // Still too early to take a conclusive view on technique or patients in aneuploidy screening Former PGS Task Force chairman considers ESHRE’s ESTEEM trial and where opinions on PGS divide Despite several concluded trials and others known to be ongoing (or planned), many questions related to aneuploidy screening of preimplantation embryos remain unresolved. However, some questions have been answered. First, the reasons for aneuploidy screening remain valid. These aim to increase the live birth rate or decrease the miscarriage rate, to diagnose live born trisomies or to look for the best embryo for single embryo transfer. Second, it has taken more than 10 years and 13 randomised controlled trials to show that the initial PGS approach applied to both good and poor prognosis patients did not work. In all of these studies FISH was used to screen a limited number of chromosomes in one or two blastomeres biopsied during cleavage. Metaanalysis has subsequently shown that PGS using FISH significantly lowered live birth rate after IVF Aneuploid polar for women of advanced maternal age. body as determined Why were the results of these studies so by array CGH disappointing? Several reasons have been analysis. 16 JOEP GERAEDTS; ‘THE MOST EFFECTIVE WAY TO RESOLVE THE DEBATES ABOUT PGS IS TO PERFORM WELL DESIGNED RANDOMISED CLINICAL TRIALS.’ suggested: the FISH method is not very accurate; not all chromosomes have been tested; the biopsied blastomere is not a true representation of the embryo at the 8-cell stage because of mosaicism; and the biopsy itself might cause harm and negatively influence the developmental potential of the embryo. Despite these results, ESHRE remained convinced that ‘the most effective way to resolve the debate about the usefulness of PGS is to perform well-designed and well-executed randomised clinical trials’. And today there are a number of permutations and combinations that can be studied. FISH can be replaced by several technical approaches which have in common the ability to target all chromosomes at the same time. Furthermore, several types of biopsy are possible one or both polar bodies, blastomere and trophectoderm biopsy. It is in the selection of the most effective technique at the most appropriate stage of embryo development that the current questions on PGS remain unresolved. After ESHRE's PGS Task Force published results from a pilot study ESHRE started a multicentre RCT using microarray technology on both polar bodies. Elsewhere, however, the number of other registered multicentre trials is disappointingly low. So it is still too early to say which approach will prove to be the best - and the possibility that this will very much depend on each individual situation cannot be excluded. For example, the indication might have to be taken into account. Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:03 Page 17 Polar body biopsy might be better suited for those patients of a higher maternal age, while trophectoderm biopsy might be better for recruiting the best embryo for single embryo transfer in younger patients. Some authors have suggested that vitrification and serial transfer of all embryos are likely to give patients the best chance of successful pregnancy, which implies they would be better off without aneuploidy screening. It is indeed the case that a highly effective and efficient cryopreservation protocol such as vitrification is compatible with the transfer of unselected embryos in subsequent frozen replacement cycles without impairing (and possibly improving) pregnancy rates. However, at a higher maternal age, the time to pregnancy is very important and can only be reduced substantially by embryo selection. Without selection, many costly months may be lost. Indeed, from the results of ESHRE's pilot study (of polar body analysis by array CGH) it was clear that at an average maternal age of 40 years around 75% of oocytes bear chromosomal abnormalities. This suggests that, by transferring each embryo one by one, many menstrual cycles will be lost unnecessarily as a result of implantation failure or miscarriage. Furthermore, the psychological burden of repeated implantation failure and spontaneous abortion of a muchwanted, clinically recognised pregnancy is severe. The aim of testing is not only to establish a pregnancy but to select the best embryo for a healthy singleton birth. Not all abnormalities are lethal, and screening for aneuploidies can reveal trisomy 21 conceptuses and other viable chromosome abnormalities, especially in women of increased maternal age. Last but not least, the costs of vitrification include two ultrasound examinations, medications, embryo warming and culture, and embryo transfer. Besides these direct costs, the indirect costs, including lost wages during treatments and child care, should also be taken into account. On the other hand, we may well now expect a further reduction in the costs of array technologies or 24 chromosome screening. PGS aims to improve the efficiency of assisted reproduction, which can be achieved in two ways: first to select at the level of the embryo to be transferred; and second to select at the level of the patient to be treated. Both these considerations in the outcome of ESHRE's array CGH pilot study were behind the design of a randomised clinical trial in women with advanced maternal age. This trial, known as ESTEEM, has two aims: first, to assess the impact of 24-chromosome polar body PGS on time to pregnancy and live birth rates; and second to estimate whether consistent oocyte aneuploidy in one cycle is predictive of consistent aneuploidy in future cycles. This trial is now well under way. But if the latter aim proves the case, almost half the patients should be counselled to stop IVF or look for alternative forms of treatment, such as oocyte donation. But until the results of the trial are known, it is still premature to put forward firm conclusions. Joep Geraedts Chairman ESTEEM Steering Committee New ESHRE guidelines on endometriosis completed New ESHRE guidelines on the Management of women with endometriosis are now in their final stages of correction. The guidelines are the first to be produced in accordance with the 12-step process ESHRE’s manual for guideline development, which include the formulation of key questions, literature search, evaluation of evidence, writing recommendations and a broad open review. The new guidelines are based on 22 questions posed by the development group, which was chaired by Gerard Dunselman from Maastricht University Medical Centre, and patient organisations. The final version makes 22 grade A recommendations (from a total of 82); the 2005 version made a total of 15 grade A recommendations (from a total of 36). The guidelines were available for review between February and April this year and in all 61 reviewers supplied comments. Recommendations on diagnosis, symptoms, pain relief and treatments (including ART) are included. Once approved by ESHRE’s Executive Committee, the guidelines will be submitted to Human Reproduction for publication and will also be freely available to ESHRE members via the website. After one year they will be freely available, and available soon as a consultation app for smart phones and tablets. Focus on Reproduction September 2013 17 E INNER sept13_nwp_50939 22/08/2013 13:03 Page 18 // PARAMEDICAL GROUP // Defining competencies and role requirements for ESHRE nurse certification in Europe ESHRE Nurse Certification The working group for nurse certification is now developing requirements for accreditation and a structure for the programme, and planning the practical steps of design and procedure for implementation. This month (September) there will be an expert meeting for European nurses for which a mailing has been sent to Committee of National Representative (CNR) members to collect contact details of nurses’ organisations throughout Europe. We hope to invite one nurse from each country, who will be asked to complete a questionnaire from which a first draft of the logbook will be prepared. The certification programme will be launched during next year’s annual meeting in Munich and promoted at all activities involving the Paramedical Group and through national fertility societies and Fertility Europe. Certification is not only important for the professional competence of nurses, but also for the provision of high-quality and safe treatments for patients. We have asked the SIGs Ethics & Law and Psychology & Counseling and our clinical adviser Anja Pinborg to provide samples for our pool of multiple choice questions. We need to ensure that there is published evidence on each correct answer. Following are some examples, on which topics good knowledge will be required: l Epidemiology of infertility l Anatomy and pathology of the reproductive system l Diagnosis l Male and female reproduction l Quality assurance l Guidelines and clinic-specific standard procedures l Legislation and ethics l EU directives and national legislation l Psychosocial support interventions l Research l Ultrasound There will be only one level for the certification exam (and not at senior and clinical levels as for the embryologists). Paramedical Board membership One of our Board members will be stepping down next year 18 E OUTER Hands-on oocyte vitrification at this year’s precongress course. in Munich and we will therefore require a nurse replacement. We will see the candidates at our board meeting in Spring 2014, and the selected candidate will be confirmed as a Board member at the Group’s Annual General Assembly in Munich. Paramedic members of ESHRE - ideally a nurse or midwife - are now invited to apply for this vacant position. It’s a commitment of four years, with a possible re-election for four more years. Those interested should contact me at [email protected]. Annual meeting London A total of 145 people registered for our precongress course in London on oocyte vitrification. There was a very positive feedback from participants, and we would like to thank the many companies who demonstrated their different devices. Together we had an interactive session in which delegates were split into working groups for practice and discussion with the companies. There was an increase in the number of paramedical abstracts submitted for the main programme and the quality of the lab abstracts was much higher than in previous years. The paramedical invited sessions were all excellent – we would also like to thank the speakers. All the sessions were well attended. Seven presentations were considered for this year’s two awards for paramedics (each of €2000) - for the best oral presentation by a nurse, presented to Hetty Ockhuysen from the Netherlands), and for the best oral or poster presentation made by a laboratory technician, won by Bart Desmet from Belgium. Helle Bendsten Chair Paramedical Board Focus on Reproduction September 2013 sept13_nwp_50939 23/08/2013 10:49 Page 19 PGD CONSORTIUM Reformed Steering Committee sets out renewed priorities under restored full power Last year the PGD Consortium’s Steering Committee was unable to function on full power because of changes to its organisation. Now, with just five elected and ‘active’ members (Jan Traeger-Synodinos, Edith Coonen, Sioban Sen Gupta, Martine De Rycke and Céline Moutou, with the support of ESHRE’s science manager Veerle Goossens) the down-sized Committee is finally ready to go again! At our recent update meeting in London, we had the fruitful input of many of those who attended, including the recently retired members Francesco Fiorentino, Georgia Kokkali, Katerina Vesela and Pam Renwick. The Steering Committee also welcomed Ursula EichenlaubRitter as the new Co-ordinator of the SIG Reproductive Genetics. She will join the non-voting Committee members Joyce Harper (Past Chair), Cristina Magli (ESHRE Executive Committee liaison) and Joep Geraedts. The collection of data XIV has continued as usual, but the cleaning and analysis of both data XIV and data XIII are behind schedule. However, we wish to acknowledge the effort of all contributing centres and aim to address the lag as soon as possible by helping Veerle Goossens, who bears the major brunt of this gigantic task. If we include the cycles submitted for data XIV (PGD cycles carried out between January and December 2011 with babies delivered up to 2012) the Consortium now has information on almost 52,000 cycles, providing an extremely valuable resource for data mining and for following trends in PGD practice. As reported in the last issue of Focus on Reproduction, our data mining effort is looking at data collection IV through to XI (>29,000 cycles). For future data collections, we hope to have an on-line data submission platform ready for the end of 2014. Celine Moutou is coordinating both of these huge projects. However, the data collections do not represent real-time trends in PGD. So for this reason the Steering Committee has decided to start a working group to monitor new technologies in PGD, chaired by Martine De Rycke. The aim is to gather up-to-date information by the end of 2013 on developments on all aspects of PGD (IVF/ICSI, biopsy practice and genetic testing strategies and technologies). This will probably be done through a questionnaire, and, to encourage Consortium-wide participation, it was decided that centres returning questionnaires will be included for authorship in any publications arising from this survey. All Consortium members should look out for the questionnaire, which we plan to e-mail to everyone in early October, with a deadline for completed questionnaires by mid-November. Other new working groups are also planned to support Focus on Reproduction September 2013 Evolution of Consortium cycle data 1997-2011, with PGS still the major indication, albeit in slight relative decline. Cumulatively, the Consortium now has information on almost 52,000 cycles. the continued generation and collection of high quality data. One plans to follow-up PGD cycles for HLA, chaired by Jan Traeger-Synodinos. The aim is to evaluate how often PGD for HLA achieves the ultimate clinical utility, which is to cure a sick child with a matched bone-marrow transplant following selection and birth of an HLA-compatible sibling. Another plans to look at collaborative working practices between genetics and IVF teams when delivering a PGD service (to be chaired by Sioban SenGupta). Again all Consortium members should look out for (e-mail) notification of participation in both of these projects. The Consortium Webpage is also being updated, and will be curated by Edith Coonen. Finally, with respect to the ‘education’ aims of the PGD Consortium, the Steering Committee plans to make, in collaboration with the SIG Reproductive Genetics, some short e-lectures relating to basic aspects of PGD to be uploaded to the Consortium webpage this autumn. In addition the first interactive webinar to initiate exchange of experience between PGD Consortium members is planned before the end of this year. The Steering Committee also wishes to emphasise that the Consortium is an important forum for all PGD practitioners to exchange data, experiences and valuable expertise. Thus the new Committee wants to encourage greater participation of member centres, not only in the data collections but also in other working group activities. Joanne Traeger-Synodinos Chair PGD Consortium 19 sept13_nwp_50939 22/08/2013 13:03 Page 20 SPECIAL INTEREST GROUPS // REPRODUCTIVE GENETICS // New report on the interface of genetics and ART Coming up in September in Publications Steering committee Prague is a Campus workshop The results of an expert meeting in Ursula Eichenlaub-Ritter (DE), Co-ordinator organised by the SIG RG and PGD March between ESHRE and the Claudia Spits (BE), Deputy Consortium on the Application and European Society of Human Tania Milachich (BG), Deputy challenges of emerging technologies Genetics to discuss the interface Georgia Kakourou (GR), Junior Deputy in preimplantation and prenatal between ART and genetics has been Joyce Harper (GB), Past Co-ordinator diagnosis, with local organisers approved by ESHRE’s Executive Milan Macek and Katerina Vesela. Committee and will be published We have also applied for a Campus workshop with the shortly in Human Reproduction and the European Journal SIGs Stem Cells and Andrology and Task Forces Basic of Human Genetics. Titled ‘Current issues in assisted Science and Fertility Preservation for early summer 2014 reproduction and genetics in Europe; research, clinical on Stem cells: origins, genetics, properties and significance practice and policy’, the report has been authored by Joyce for fertility preservation organised by Karen Sermon, Harper, Karen Sermon, Milan Macek Jr, Joep Geraedts, Ursula Eichenlaub-Ritter, Stephan Schlatt and Helen Luca Gianaroli, Anna Viega, Claudia Spits, Gary Harton, Picton. Stéphane Viville, Joris Vermeesch, Inge Liebaers, Michael However, an update workshop on PGS originally Morris, Helena Kääriäinen, Heather Skirton, Francoise planned for 2014 has been postponed to await completion Shenfield, Pascal Borry, Martina Cornel, Sirpa Soini, Tanya of several randomised trials, but the event is planned for Milachich, and Jorge Sequeiros. 2015 organised by Francesco Fiorentino and the PGD Another paper on the ethical issues raised by the genetic Consortium. screening of gamete donors and based on a joint meeting in And a Campus course on Epigenetics in reproduction is Maastricht last year of the SIGs RG and Ethics & Law is planned for autumn 2014 in Lisbon (with local organiser now in preparation. Carlos Plancha) together with SIG Embryology and Task Force Basic Science. Training We expect that the precongress course on The current Our precongress course on Genes and epigenetic status of PGD and PGS planned for the next annual mechanisms of infertility and how to minimize the risks in meeting in Munich in 2014 is likely to attract a wide London 2013 was well attended and led to animated audience of those working in PGD and embryology, but discussions. should also prompt new discussions on outcomes after PGD/PGS, and the consequences of aneuploidy in the preimplantation embryo; also on the agenda are the relevance of mitochondrial disorders and ethical dilemmas raised by PGD/PGS. Joyce Harper is leading our activites in elearning and we hope to have the first modules ready by the end of 2013. Speakers at the SIG RG precongress course in London on the genetic and epigenetic causes of infertility with members of the steering committee: from left to right, Thomas Haaf, Robert Feil, Wendy Dean, Stéphane Viville, Gudrun Moore, Joop Laven, Joyce Harper, Ursula Eichenlaub-Ritter, Alan Handyside, and Tania Milachich. 20 Organisational changes The Steering committee is now headed by Ursula Eichenlaub-Ritter as the new Coordinator of the SIG, replacing Joyce Harper whose two-year term came to an end in London. Claudia Spits and Tania Milanich (former Junior Deputy) become the SIG’s Deputies, while Georgia Kakourou was confirmed as the new Junior Deputy at our business meeting in London. Ursual Eichenlaub-Ritter Co-ordinator SIG Reproductive Genetics Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:03 Page 21 // REPRODUCTIVE SURGERY // ESHRE certification in reproductive endoscopic surgery off to a welcome start in London The highlight of this year’s annual meeting was undoubtedly the kick-off of ESHRE’s Certification on Reproductive Endoscopic Surgery (ECRES) programme. The SIG RS and ECRES steering committee worked very hard to get the programme under way and in time for London. However, 25 doctors from various countries took the first validated tests for their hand skill abilities in hysteroscopy, laparoscopy and laparoscopic suturing. The candidates were in addition tested in theoretical examinations with 100 multiple choice questions. A detailed description of the ECRES programme can now be found on the ESHRE website, where an e-learning platform will be soon available, with RS tutorials loaded for e-learning purposes. All speakers presenting relevant lectures at ESHRE Campus events and ESHRE annual meetings have been asked to give Central Office five multiple choice questions related to their presentation. This pool of questions will be validated according to international standards and used for learning and testing purposes. Video presentations and classic surgery cases will also be collected, classified and evaluated for learning purposes. Live surgery in London direct from the Heilig Hart hospital in Leuven, Belgum. As ever, well attended, with much participant interest. equipment used. Dealing with complications, they explained their decisions and provided tips and tricks. The oral presentations comprised the top score submitted papers in reproductive surgery, both in laparoscopy and hysteroscopy. The high attendance and interest showed during discussion of the presentations reflects the ever increasing interest in endoscopic surgery, especially by young gynaecologists. Interesting data were presented on the de-torsion of ovarian cysts and the preservation of primordial follicles, even after 72 hours of torsion. Among other topics addressed were reproductive outcomes after the hysteroscopic treatment of uterine malformations as determined by systematic review and meta-analysis. The RS precongress course attracted 152 participants, our highest attendance ever. Congenital uterine anomalies The new classification on congenital uterine anomalies (CONUTA) was extensively presented and discussed by participants. Their simultaneous publication in Human Other activities in London Reproduction and Gynaecological Surgery raised much The live surgery was session organised, performed and cointerest and everybody agreed that a new era for clinical ordinated by Stephan Gordts from the Heilig Hart research on uterine anomalies should now begin based on Hospital in Leuven, Belgium. Top quality and state-of-thethe new classification. Already the SIG RS is planning a art endoscopic surgery was performed by Prof Arnaud web-based research logbook where gynaecologists with Wattiez (FR), Michelle Nisolle (BE), Jaine Ferro (ES) and infertile patients with uterine anomalies defined by the new Sylvie Gordts on infertile patients with rectovaginal classification can insert patients’ clinical data, treatments endometriosis and endometrioma cysts. In addition and follow-up in a prospective way. We believe that such a hysteroscopic myomectomy, septectomy, tubal sterilisation research programme will generate a reversal and transvaginal endoscopy large number of cases in a short were also demonstrated. The live Steering committee period of time and be able to answer surgery session this year was TC Li (GB),, Co-ordinator questions of primary importance. attended by 800 participants, who Antoine Watrelot (FR), Deputy Vasilis Tanos could take part interactively with the Gregoris Grimbizis (GR), Deputy Past Co-ordinator surgeons explaining their operation Sotirios Saravelos (GB), Junior Deputy SIG Reproductive Surgery strategy prior to the procedure and Vasilis Tanos (CY), Past Co-ordinator demonstrating the tools and Focus on Reproduction September 2013 21 sept13_nwp_50939 22/08/2013 13:03 Page 22 SPECIAL INTEREST GROUPS // REPRODUCTIVE ENDOCRINOLOGY // Record turnout for London precongress course Our precongress course in London lifestyle and endocrine disruptors Steering committee on Ovarian stimulation for ART pre- and periconception, the value of Efstratios Kolibianakis (GR), Co-ordinator how to achieve efficacy and safety treating subclinical hypothyroidism, Frank Broekmans (NL), Deputy was the best attended of all ESHRE immunological and endocrine Daniela Romualdi (IT), Deputy courses this year and, with 560 aspects of implantation, the Tehri Piltonen (FI), Junior Deputy participants, broke all records for endocrinology of pregnancy, genetic Georg Griesinger (DE), Past Co-ordinator ESHRE workshop attendance. The markers of early pregnancy success, quality of the presentations and the and early pregnancy progesterone. high level of discussion were very stimulating. This year we introduced an e-voting system on SIG RE business meeting in London controversial topics, which encouraged interaction with the Under the existing ESHRE regulations each SIG is allowed lectures and will be endorsed for future SIG RE meetings. only one Campus meeting per year, which is somewhat restricting for our group, the largest amongst ESHRE Campus events in 2013 SIGs. On the other hand, such a regulation emphasises the We encourage you to register for our Campus meeting in need for a careful selection of a topic which combines Rome on 25-26th October on Polycystic ovary syndrome: a both high scientific value and clinical importance. new look at an old subject, hosted by SIG RE Deputy During this year’s business meeting in London a call for Daniela Romualdi. The programme includes presentations proposals for a Campus meeting in 2014 - as well as for on emerging challenges in the diagnosis of PCOS, on new the precongress course in 2015 in Lisbon - was made with insights into its causes, on how to achieve and maintain a a deadline of September 2013. Please email any comments pregnancy in PCOS patients, and on the problems of PCOS or ideas to me ([email protected]). Some beyond reproduction. proposals were put forward and discussed briefly by the Later in the year, on 6-7th December, an equally business meeting, where it was also proposed for the interesting Campus will take place in Utrecht on Primary future that all such proposals should already have been ovarian insufficiency, an update and guideline presentation made in writing prior to the business meeting; this would hosted by the SIG RE Deputy Frank Broekmans. The allow for a more detailed and productive discussion. programme includes presentations on the basics of early In London Georg Griesinger (DE) stepped down as Coovarian ageing, the pathophysiology of POI and the ordinator of the SIG RE, after a very successful term, to involved genes, the clinical condition of POI, its treatment join ESHRE’s Executive Committee. Georg will serve as a and care, and on the work in progress of ESHRE’s POI Past Co-ordinator for the next two years and thus we will guideline development group. be able to share his valuable experience. Frank Broekmans (NL) will continue to be active as a Deputy, together with Precongress course 2014 Munich Daniela Romuladi (IT) who became a Deputy after serving The next pre-congress course in Munich will be on the two years as Junior Deputy. Tehri Piltonen (FI) joined the contribution of endocrinology and early pregnancy SIG RE as the new Junior Deputy. Tehri was chosen by the management to the success of an ART centre. The previous steering committee members and previous Past programme has been finalised and will focus on the Co-ordinator Adam Balen, according to the current association of gut and adipose hormones to human ESHRE regulation, from several strong candidates. reproduction, the endocrinology of obesity and its impact Stratis Kolibianakis on fertility, risk of miscarriage and child health, nutrition, Co-ordinator SIG Reproductive Endocrinology A record attendance of 560 for this year’s precongress course in London. 22 Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:03 Page 23 // STEM CELLS // Nobel prizes, major breakthroughs, exciting courses, and a new steering committee Benjamin Reubinoff presenting very These are exciting times for the stem Steering committee promising preclinical data on retinal cell field. Just a few months ago, Rita Vassena (ES) Co-ordinator regeneration with pluripotent cells. A Shinya Yamanaka and Sir John Cristina Eguizabal (ES), Deputy lively debate followed, with many Gurdon (who will be made an Karen Sermon (BE), Past Co-ordinator colleagues hoping to understand the honorary member of ESHRE next Filippo Zambelli (IT), Junior Deputy true therapeutic value of stem cells. year in Munich) were awarded the To address the ever important Nobel prize for their reprogramming question coming from clinicans - ‘This is interesting, but of differentiated cells towards pluripotency. This was an what’s in it for my patients?’ - the SIG SC together with incredible feat which turned on its head the one-way-street the Task Force Fertility Preservation organised a well concept of pluripotency and is now bearing its first attended precongress course in London 2013 on translational fruits with clinical trials announced in Japan. Pluripotent stem cells, cancer and fertility preservation: And now, in June 2013, another milestone in the field has science fact or science fiction?. Here, many scientists and been reported: Shoukhrat Mitalipov, from the Oregon practitioners from different fields learned about the Health & Science University, described the successful possible applications of stem cells in fertility preservation derivation of human embryonic stem cell lines from for both females and males; other presentations focused on human embryos generated by somatic cell nuclear transfer, the epigenetics of pluripotent cells, the stimulation a technology also known as ‘therapeutic cloning’. protocols for cancer patients and the role of cancer stem These findings, reported in the prestigious scientific cells in germline cancers, and the possible risks associated journal Cell, offer the possibility of deriving embryonicwith stem cells transplantation. like stem cells from an adult patient; if the paper is Considering the high level of interest that stem cells in confirmed by independent laboratories (some minor issues general are raising, the SIG SC has teamed up with SIGs were found in the published data) these findings open the Andrology, Reproductive Genetics, and the Task Force possibility of understanding human reprogramming, and Fertility Preservation for a new multidisciplinary Campus the production of personalised stem cell lines without workshop to be held later in 2014. More information will genetic intervention. follow in Focus on Reproduction, and on the ESHRE Although this new technology avoids the use of IVF website, so keep your eyes open for updated information embryos, it still raises a series of ethical issues related to on this outstanding learning experience. the use of human oocytes for research, and the ethical status of nuclear transfer-derived constructs. The Belgian Steering committee law on embryo research, for instance, would regard such During the meeting in London, a few changes have come constructs as an embryo, which would thus fall under the about: Karen Sermon, SIG Co-ordinator since 2010, has remit of the law. stepped down and Rita Vassena, Scientific Director at With such outstanding results in recent years, and the Clinica EUGIN in Barcelona, has now taken over. Cristina increasing investments of pharmaceutical companies in cell Eguizabal (ES), past Junior Deputy has become Deputy. therapy, we can say that stem cells are finally overtaking The new junior Deputy is Filippo Zambelli (IT). There is criticism and scepticism, with an increasing number of now an open vacancy for the position of Deputy and three clinical trials now ongoing around the world. candidates have come forward for the elections: Petra Hajkova from MRC London, a well known researcher in Clinical applications germ cell biology and epigenetics, Stéphane Viville from Following this wind of change, the SIG Stem Cells is Strasbourg, a past Co-ordinator of the SIG Reproductive making great efforts to give visibility to the latest updates Genetics and Björn Heindryckx from the Ghent University in the field, and how they relate to the everyday work of Hospital in Belgium, renowned for his research on the reproductive scientists and physicians. The stem cell molecular control of ESC derivation. All the members of session in the main program of ESHRE’s annual meeting the SIG will be shortly invited to vote and choose which in London (Are stem cells ready for the clinic?) reflected one will be our new Deputy. the many novelties in the field, with a talk by Rita Rita Vassena Vassena detailing the incredible tool that stem cell-based Co-ordinator SIG Stem Cells assays are for drug discovery and disease modelling, and Focus on Reproduction September 2013 23 sept13_nwp_50939 22/08/2013 13:03 Page 24 SPECIAL INTEREST GROUPS // ANDROLOGY // London reflects ‘very active’ research community SIGA activities in London were well precongress course programme for Steering committee attended. Our precongress course - Is Munich is now finalised and is Stefan Schlatt (DE), Co-ordinator male fertility decreasing? The latest titled: Treating the man with Willem Ombelet (BE), Deputy news suggests not… - provided a evidence based medicine. Two Jackson Kirkman-Brown (GB) , Deputy wide range of interesting material proposals for Campus workshops Victoria Sanchez (ES), Junior Deputy and very lively discussions on the in 2014 have been received on Sheena Lewis (GB), Past Co-ordinator impact of environmental exposures. donor sperm banking and novel A number of sessions in the main aspects of fertility preservation. programme also covered a range of andrological topics, There were several changes to the SIGA steering including sperm factors influencing ART outcome, committee. Sheena Lewis stepped down as Co-ordinator regulation of sperm motility, lifestyle dangers for men’s to become Past Co-ordinator and Stefan Schlatt the new fertility, methods for assessment of sperm quality, and the Co-ordinator. Willem Ombelet continues as Deputy, Lars impact of genetics in andrology. There were also Björndahl as SIGA education sub-committee member and andrological angles to a number of sessions on stem cells David Mortimer as international advisor. Jackson and fertility preservation, including a presentation on Kirkman-Brown will act as a new Deputy, and Victoria advances in male fertility preservation by the new SIGA CoSanchez as new Junior Deputy. ordinator Stefan Schlatt. Overall the representation of The steering committee is keen to strengthen its training research was excellent and the quality of the presented data activities and sperm quality control programme, and revealed a very active research community in andrology. considered the development with other organisations (WHO, International Society of Andrology, regional and national societies) a curriculum for training in clinical Steering committee andrology and spermatology. Also discussed was a At the SIGA business meeting outgoing Co-ordinator registry for drugs affecting male fertility or sperm. Sheena Lewis reported on all ongoing activities, and noted Stefan Schlatt room for improvement in the quality and selection of Co-ordinator SIG Andrology andrology abstracts submitted for the annual meeting. Our // EARLY PREGNANCY // Young scientists encouraged to submit abstracts for November We are delighted to welcome Emma Kirk from London as our new Deputy. She will reinforce the activities of the SIG EP. The new steering committee is pictured below, left to right Mariëtte Goddijn, Siobhan Quenby, Ole B Christiansen, Emma Kirk and Robbert van Oppenraaij. This year’s precongress course in London on Risk factors for early pregnancy loss - more pieces of the puzzle was fully booked with nearly 200 participants, a precongress course record for the SIGEP. The programme covered many relevant topics - diagnostic tools for diagnosis of pregnancy of unknown location (PUL), the role of lifestyle factors, and treatment in thyroid autoim24 Steering committee Mariëtte Goddijn (NL), Co-ordinator Siobhan Quenby (GB), Deputy Emma Kirk (GB), Deputy Robbert van Oppenraaij (NL), Junior Deputy Ole B Christiansen (DK), Past Co-ordinator munity and recurrent miscarriage. In November a joint Campus meeting with the Task Force Basic Science - From early pregnancy to later in life - will be held in Brussels. The concept of the developmental origins of health and disease attracts much attention, and the impact of environmental and other influences is evident in the pre-pregnancy and early pregnancy period. Topics to be covered are early implantation, the prediction of pregnancy outcome by biomarkers, and effects from preconception. We expect a lively debate on the predictive value of endometrial and embryonic markers. Young scientists working in the field of early pregnancy and e Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:03 Page 25 // EMBRYOLOGY // // PSYCHOLOGY & COUNSELLING // Another busy agenda New guideline progress With a new steering Maria José de los Santos (ES), Co-ordinator committee Sophie Debrock (BE), Deputy the SIGE Giovanni Coticchio (IT), Deputy has been Susanna Apter (SE). Junior Deputy partially Carlos Plancha (PT), Basic science renewed, so Kersti Lundin (SE), Past Co-ordinator alongside Carlos Plancha, our Basic Science representative and Kersti Lundin, our Past Co-ordinator, we welcome three new members: Susanna Apter as Junior Deputy, and Giovanni Coticchio and Sophie Debrock as Deputies, whose knowledge will ensure the SIGE continues efficiently. Our aims are to promote the educational, scientific and professional aspects of embryology by combining multiple activities, such as workshops and precongress courses, elearning platforms, guidelines and quality control, as well as certification of embryologists. We encourage you to visit our new web page, with links to recommended readings, training events, and other information. After an extremely active precongress course in London our next appointment is in Barcelona on 4-5th October for a joint event with the Paramedical Group on Introducing new techniques into the lab. Next year will bring other exciting events, particularly our time-lapse precongress course in Munich in which the results from ongoing RCTs and algorithm validation studies will be presented and discussed. In the autumn of 2014, a joint course on epigenetics with the TF Basic Science and SIG Reproductive Genetics will take place. We will also keep working on our other tasks - updating the Atlas of Embryology with new chapters – on cryopreservation and time lapse - and hopefully with new/improved/interactive pictures. We also expect to review and update the ESHRE guidelines for good practice in IVF to be beneficial to both laboratories and patients. And last but not least our e-learning programme will be introduced during the next few months, which will also provide upgrade points for the certification system. María José De los Santos Co-ordinator SIG Embryology Our well Steering committee attended Uschi Van den Broeck (BE), Co-ordinator precongress Cora de Klerk (NL), Deputy course in Sofia Gameiro (GB),, Deputy London was on top quality Mariana Martins (PT), Junior Deputy Christianne Verhaak (NL), Past Co-ordinator psychosocial care and the implementation of new guidelines. Presentations included such topics as tailored expectant management, the waiting period, and changing lifestyles. Our new guideline on psychosocial care, for which Sofia Gameiro chairs the development group, was also considered in detail and will be open for review this autumn. The business meeting in London was also the time to present the new steering committee, which now comprises Uschi Van den Broeck (NL), Cora de Klerk (NL), Sofia Gameiro (UK), and a new junior representative Mariana Martins (PT). On behalf of the new committee, Uschi thanked Chris Verhaak for all her hard work during her term of office. Next on our SIG calendar (on 14-15th March 2014) is an ESHRE Campus symposium on Fertility preservation: from technique to implementation in clinical practice, with valuable multidisciplinary contributions. The course has been jointly organised by the SIGs Ethics & Law, Safety & Quality in Art, and the Paramedical Group. All important aspects on the impact of cancer treatment on reproductive funtioning will be covered, from patient information and the decision-making process to pregnancy, from ethical and legal issues to the experience of survivors. More detailed information can be found on the ESHRE website. Soon after that our precongress course will be held in Munich. The course is titled On seeking evidence from different perspectives: patients and professionals’ views. We are hoping that this course will prove as popular and rewarding as this year’s! We are also looking forward to hearing your suggestions - please let us know what you think our SIG could deliver to you. We hope to see you again in Munich and Lisbon. Mariana Martins Junior Deputy SIG Psychology and Counselling Steering committee developmental origins of health and disease are encouraged to submit an abstract for presentation during the Young Scientist Session on 28th November. The deadline for submission is 25th October. Four abstracts will be selected for oral presentation, with 10 minutes presentation and five for discussion. Some abstracts will be selected as poster presentation. Abstracts can only be Focus on Reproduction September 2013 submitted online. For availability of places please check the ‘Calender’ section of the ESHRE website. So, we hope to see you at this important Campus meeting, and please take a look at our web page to see what else is going on. Mariëtte Goddijn Co-ordinator, SIG Early Pregnancy 25 sept13_nwp_50939 22/08/2013 13:03 Page 26 IN PROFILE continuum of women’s reproductive health. In time a broad editorial base will surely reflect the interdisciplinary range of today’s reproductive medicine. ESHRE’s review journal Human Reproduction Update has for several years led the impact factor categories of Reproductive Biology and Obstetrics & Gynecology - and by a long way. But, at a figure of 8.857, there’s still room for progress, says new editor-in-chief Felice Petraglia. He tells Focus on Reproduction how he hopes to take the impact factor even higher. And ESHRE's core readership? Well, we’ve already reached the top of our core readership. You can see that in the impact factors. In Ob/Gyn and reproductive biology we’re at the top. But in the other fields we’re not widely cited. Why do the endocrine journals have more citations - because of cardiovascular medicine, osteoporosis . . . So what we should declare is that Update is not only assisted reproduction, not only infertility, but a continuum of women’s health - from contraception to the menopause. That’s what I want people to know. Uplift for Update Editor’s prescription for a double digit impact factor FoR: You've almost completed your first year as editor of the world's leading journal in reproduction. How have you found it? FP: It was very difficult to follow the former editors John Collins and Bart Fauser. They had 12 years of tremendous success and brought Human Reproduction Update to the very top. So my problem is trying to improve on what they had done already. And has the problem been resolved? No, but I do believe we can make some progress by broadening the scope of the journal. That would provide an 26 opportunity for more citations from more journals - and of course it would extend our readership into a broader range of interests. This is something that Update can realistically do, which other more specialist journals cannot. But it won’t be easy. There’s still a widespread belief that Update is a journal only about IVF. But given the past achievements of Update, do you really think it's a good idea to broaden its scope in this way? In terms of readers, I think the answer is yes. IVF doesn't exist in a vacuum, it’s part of a much grander lifetime And is that how you'll commission papers? Well, the biggest change we have made is to open submissions to everyone. So anyone from any discipline can submit a proposal to the journal. This has been an important change, and we have received more than 80 proposals during the first six months. Yes, we have to commission, but I also have to say that Update is open, you don’t need an invitation. So how will this work out? What proportion of papers will be commissioned or offered? I think around 60% will be openly offered and 40% commissioned. So our priority is not to commission but to communicate how the journal works - that it’s open to many clinical and scientific topics related to reproductive health. Update's impact factor is still very high, but it has gone down a little from last year. Do you see that as the start of a trend? I said last year that my aim is to see the impact factor in double digits, and I hope that this is still possible. What the latest analysis told me is that we increased the number of papers in 2011. In the past we were publishing 45 or so papers each year, but in 2011 we published 65 - that’s 50% more papers, and I’m sure that diluted the impact of each paper. So if you'd published fewer papers the impact factor would not have dropped? Exactly. So over the next few years I’d like Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:04 Page 27 to see bigger and better reviews, but fewer of them. More comprehensive, more authoritative, a strong first author - the last word, in fact, which everyone wants to read, download and cite. That’s how we’ll reach an impact factor of 10. On a more personal note, has editing the world's leading journal in reproduction made a difference to your working life? Yes, it is certainly changing. Increasingly I feel I must check what’s happening in the rest of the medical journals and speak to other editors to get a feel for what’s going on. I also like to be on the lookout for new authors, the new young PhDs. And this takes time? Yes, more than I expected. It’s not just about considering new submissions, but looking at the broad field and thinking how we can keep ahead. I have to be receptive to all possibilities, to consider topics that people are interested in. By training and background you're an obstetrician and gynaecologist, with a special interest in endometriosis. Are these the right credentials for the job? In my early career I did a lot of work in neuroendocrinology and stress and I’ve followed that theme throughout my working life - how this model of the brain, hormones and stress can affect fertility, pregnancy, endometriosis. I can see the same thinking in developments in epigenetics. So my background is varied, but I think this variety will be helpful to provide the link between these disciplines. You were formerly Editor-in Chief of the Journal of Endometriosis. How is editing Update different? It’s Manchester United versus Siena. Update is the number one journal, and most people are very happy to be involved. Any problems about accepting the job? It was truly a great honour. And very unexpected, believe me. I haven’t done a lot with ESHRE, which is why I was even more surprised. I have in the past been involved with the SIGs in reproductive Focus on Reproduction September 2013 endocrinology and endometriosis, but not much more. So when I was invited to edit the journal it was a great surprise. And Italy? Is it still difficult to be a gynaecologist there? The legal changes in 2004 were difficult, and everyone working in IVF had to adapt - but we’re slowly moving back to where we were. I think we adapted well and I haven’t seen any centres fail. As in many countries, women are going abroad for egg donation. This is the major complaint in Italy - PGD, embryo freezing, we’re dealing with them, but not with egg donation. Otherwise, medicine does well in Italy. We spend a lot on our public health service, and there are many public services for infertility. But we are beginning to see consolidation of these services, to concentrate expertise in fewer centres. We don’t need an IVF centre every 20 kilometres. And home? My home is Tuscany, right in the city of Siena. I trained there in gynaecology, but immediately after graduating I began basic science research in Milan, and then moved for three years to the Salk Institute for Biological Sciences in California. I worked in neuroendocrinology and reproduction before returning to Italy - and finally, after 20 years, came back to Siena as head of Ob/Gyn. Has editing Update taught you any more about ESHRE? Yes, the Society has a very broad vision in its outlook - much more than the American society, for example. Paramedics, developing countries, special clinical interests, basic science, many learning courses - they’re all part of ESHRE. Undoubtedly, ESHRE is now one of the best European societies, with three top journals and a great example how Europe can be representative throughout the world - as a single entity without national borders. The Society’s aim to increase its number of guidelines is a great opportunity to enhance its appeal throughout the world - and at the same time give us well cited papers for our journals, especially Update! The Proust questionnaire* What's your greatest personal strength? Self control . . . and your greatest weakness? Impatience Your favourite pastime? Reading books If not Felice Petraglia, who else would you be? The Pope What book are you reading now? French Suite by Irène Nemirovsky What was the last movie you watched? The Best Offer by Giuseppe Tornatore Your favourite composer Giacomo Puccini . . . and favourite artist? Beato Angelico Your favourite food? Steak and fries Herbal tea, or a glass of chianti? Chianti classico riserva Your favourite place in the world? Tuscany . . . and your latest holiday destination? Boston, USA A personal motto? Persevere and continue * A personal questionnaire celebrated and originally made popular by the French writer Marcel Proust 27 sept13_nwp_50939 22/08/2013 13:04 Page 28 FEATURE Female obesity is clinically challenging, and controversial, with the risk of subfertility far greater in obese women than in those of normal weight. José Bellver from IVI Valencia in Spain reviews its multiple roles in reproductive function and finds evidence of ovulatory, endometrial and embryonic effects. Fertility and female obesity O besity has increased sharply in both developed and developing countries over the past decades. Recent statistics show that more than 30% of adults and around 17% of children and adolescents in the USA are obese, some 78 million adults and 13 million children, with a similar distribution between male and female.1 This is a trend apparent not only in the USA but throughout the developed world. Moreover, although some recent studies suggest that levels of childhood obesity have plateau’d in the last decade in some western countries (USA, western Europe, Australia, Japan), renewed increases are still anticipated over the coming years, especially in developing areas such as Africa.2 Such figures explain why the prevention and control of this pandemic have become such a worldwide public health priority. Conception As a systemic disease, obesity affects every tissue and organ of the body, inducing or exacerbating many co-morbidities such as cardiovascular and cerebrovascular diseases, type 2 diabetes, sleep apnoea, gastrointestinal diseases, osteoarthritis and cancer. The reproductive system is similarly affected. GETTY IMAGES Natural conception Different studies have shown that the risk of sub- and infertility is almost three times greater in obese women than in those of normal weight. Recently, Polotsky et al showed that adolescent obesity was related to a four-fold increased risk of lifetime nulligravidity (no pregnancy) and to a threefold increased risk of lifetime nulliparity (no live birth).3 Similarly, Wise et al demonstrated a longer time to pregnancy in 28 Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:04 Page 29 overweight and obese women than in normoweight controls in an internet-based prospective study. This effect was found to be stronger in nulliparous than in parous women and to increase with BMI.4 Classically, the decreased chance of conception in obese women has been related to a higher prevalence of ovulatory infertility. However, recent studies have shown that even obese ovulatory women who present with regular menses still have a significant reduction in spontaneous conception rates. Indeed, the cumulative pregnancy rate within a year seems to decline by 4% for each single unit of BMI increase over 29 (as measured in kg/m2).5 This effect is similar to that seen with each year of advancing maternal age. Thus, despite the fact that ovulatory infertility is significantly prevalent in obese women, other mechanisms affecting the oocyte, the embryo or the uterine environment may also be involved in their poor reproductive outcome. This effect seems to be even worse when both partners are obese and share a similar lifestyle.6 Assisted conception In some mild assisted conception treatments - such as IUI after ovulation induction with clomiphene citrate or gonadotropins - reduced conception rates have been described in obese women.7,8 This effect seems to be enhanced by the central distribution of fat. Zaadstra et al showed in IUI cycles with or without clomiphene citrate that, for each 0.1 unit of increase in the waist-to-hip ratio, the odds ratio of conception per cycle significantly decreased by 30%.9 Similarly, higher-rank assisted conception cycles (IVF and ICSI) have also been shown to be affected by female BMI. In the largest published single-centre study on the effect of female BMI on IVF/ICSI outcome, which included 6500 cycles of IVF and 81,581 oocytes and their corresponding embryos, implantation, pregnancy and live birth rates all fell with an increase in female BMI.10 Similarly, a recent meta-analysis including 33 studies and 47,967 IVF/ICSI treatment cycles found reduced clinical pregnancy rates and live birth rates in overweight and especially obese women when compared with normo-weight controls.11 Another collaborative study involving 345 US clinics and 45,163 embryo transfers also reported a dose-response relationship between female BMI and intrauterine gestation.12 So, the higher the BMI, the less chance of pregnancy. These effects may be exacerbated by obesity in the male partner. Indeed, a recent report showed that increased female and male BMI, both Focus on Reproduction September 2013 independently and in combination, negatively affected live birth rates after IVF treatment.13 However, despite a suspicion of gamete and embryo damage induced by female or male weight excess, no consensus has as yet been reached on the specific alterations responsible for these outcomes. Some authors have proposed that the classical static morphological criteria employed in IVF labs for gamete or embryo selection are not useful for assessing the negative effect of obesity on them. This is one important reason why new means of embryo assessment such as time-lapse analysis have been introduced in obese women although so far without success.14 Another complication associated with female obesity is the ovary’s reduced response to ovulation induction or controlled ovarian hyperstimulation. A ‘gonadotropin-resistance’ syndrome was described 20 years ago and is associated with a higher consumption of drugs, higher cancellation rates, lower ovarian response, and fewer oocytes and embryos available for transfer or cryopreservation. This poor ovarian response has also been associated with some obesity-related metabolic disturbances, such as insulin resistance and hyperleptinemia, whose expensive treatments with poor results have become an important issue, especially in public health services. Endometrial receptivity The role of the endometrium in the reproductive performance of obese women has been a matter of debate over the past decade, mainly because of the contradictory results from different studies using the ovum donation model. From a clinical point of view ovum donation is indeed the best model to separate the effects of the oocyte or embryo from the uterus in the assessment of any parameter of interest, because only oocytes from healthy, young and normo-weight donors are used. However, Fetal/neonatal Congenital anomalies - Neural tube defects - Omphalocele - Congenital heart disease Fetal distress Macrosomy (>4500 g) Hydramnios Shoulder dystocia Hypoglucemia Jaundice Postnatal Obesity Type 2 diabetes Cardiovascular diseases Metabolic syndrome Suspected: - Osteoporosis - Cancer - Neurodevelopmental delay - Ageing The short and long-term increased risks of maternal obesity in the offspring. 29 sept13_nwp_50939 22/08/2013 13:04 Page 30 methodological problems in these studies have hindered consensus. This year at the ESHRE annual meeting we described a large 12-year retrospective cohort analysis of 9587 first cycles of ovum donation performed in three clinics of our institution in Spain. Only ova from normo-weight donors were employed. Recipients included lean women with BMI <20 kg/m2 (n = 1458; 15.2%); normo-weight women with BMI 20-24.9 kg/m2 (n = 5706; 59.5%); overweight women with BMI 25-29.9 kg/m2 (n = 1770; 18.5%); and obese women with BMI ≥30 kg/m2 (n = 653; 6.8%). Implantation, pregnancy and live birth rates were all significantly reduced as recipient BMI increased, indicating a direct negative effect of female weight excess on endometrial receptivity.15 We had previously shown a dysregulation of endometrial gene expression during the window of implantation in obese infertile women, especially in association with polycystic ovary syndrome, indicative of an alteration in endometrial receptivity induced by female obesity.16 Pregnancy Female obesity has an impact not only on how the pregnancy is achieved but also in how it develops. In the first trimester of pregnancy some metaanalyses have shown an increased risk of miscarriage in natural and assisted conceptions. However, not all studies have observed this effect. In addition, the main cause of first-trimester miscarriage - chromosomal abnormalities – does not seem to be increased in spontaneous abortions of obese women when compared with normo- Obesity Natural conception INFERTILITY Ovulation induction Gonadotropin Ovarian stimulation resistance REDUCED PREGNANCY RATES l Increased miscarriage rates l Increased obstetric complications l Reduced healthy live birth rates The ‘bottle-neck’ effect of female obesity on conception and live birth rate. 30 JOSE BELLVER: ‘DIFFERENT STUDIES HAVE SHOWN THAT THE RISK OF SUB- AND INFERTILITY IS ALMOST THREE TIMES GREATER THAN IN THOSE OF NORMAL WEIGHT.’ weight controls.17 It may well be, therefore, that an abnormal endocrine and/or metabolic environment in which the embryo develops may be responsible for an increased risk of miscarriage in some specific subgroups of obese women, but perhaps not in all of them. An increased risk of congenital malformations and second and third trimester obstetric complications has also been described in obese women after either spontaneous or assisted conceptions. Most are an expression of the metabolic syndrome of obesity during pregnancy together with an underlying maternal subclinical inflammation and vascular dysfunction.18 Complications include hypertension, gestational diabetes, pre-eclampsia, thromboembolism, fetal macrosomia, urinary tract infection, preterm labour and delivery, sudden and unexplained intrauterine death, operative vaginal deliveries, Caesarean section delivery, shoulder dystocia, postpartum haemorrhage, postoperative wound infection and dehiscence and endomyometritis in the puerperium. As a consequence, some authors have determined a five-fold greater cost of prenatal care in obese women than in those of normal weight. The combination of lower implantation and pregnancy rates, possibly higher miscarriage rates, and increased maternal and fetal complications reduce the probability of a healthy live birth. Indeed, live birth rates have been described as significantly reduced in obese women in a doseresponse manner.12 Postnatal life The negative influence of female obesity does not end with the delivery of the baby. Some recent studies have determined an increased risk of metabolic and non-metabolic diseases during the childhood, adolescence and adulthood of Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:04 Page 31 Strategy Pros Cons Lifestyle therapy Non-invasive Re-education in healthy lifestyle habits Psychological support Proven efficacy in infertility High abandon rate Average time six months Mild to moderate weight loss Pharmacotherapy Potential improvement in weight reduction in association with lifestyle therapy Little weight loss Rapid weight regain after discontinuation Frequent side effects Not advised around conception No proven benefit in fertility Bariatric surgery Significant weight reduction Faster weight reduction Long sustainable weight reduction Reduction/elimination of co-morbidities Improvement in quality of life Potential improvement in fertility and in some pregnancy complications Invasive High morbidity Non-negligible mortality 5-10% failure rate Chronic malabsorption syndrome Controversial impact on fertility and obstetrics Unknown long-term effects on offspring Waiting period before conception Pros and cons of weight reduction strategies for obese and infertile women. offspring of obese women. Both perinatal underand overnutrition in the mother have been related to metabolic diseases in the postnatal life of the descendants, probably because of epigenetic modifications to the embryo genome - so-called ‘nutritional programming’. Indeed, several recent reports have associated obesity in pre-pregnancy and pregnancy with a minimum two-fold increase in the risk of obesity, type 2 diabetes, cardiovascular disease and metabolic syndrome in the offspring.19 In addition, some other nonmetabolic diseases have been epidemiologically associated with maternal obesity, which could be related to in utero metabolic disturbances, chronic inflammation and oxidative stress. These diseases include breast, liver and colorectal cancer, osteoporosis, neurodevelopmental disorders, and ageing. Cost implications Wang et al recently developed a simulation model to project the probable health and economic consequences of the next two decades from a continued rise in obesity in two ageing populations - in the USA and UK – relative to cardiovascular diseases, diabetes and cancers. These trends project 65 million more obese adults in the USA and 11 million more in the UK by 2030 - and, as a result, an additional 6–8.5 million cases of diabetes, 5.7–7.3 million cases of heart disease and stroke, 492,000–669,000 additional cases of cancer, and 26–55 million Focus on Reproduction September 2013 quality-adjusted life years lost. The combined medical costs associated with the treatment of these preventable diseases are estimated to increase by $48–66 billion/year in the USA and by £1.9–2 billion/year in the UK by 2030.20 In the field of fertility, Koning et al assessed the economic consequences of overweight and obesity in a hypothetical cohort of 1000 women; live birth was decreased by 14 and 15% in overweight and obese anovulatory women, respectively, and by 22 and 24% in overweight and obese ovulatory women, when compared to normo-weight controls. These outcomes were also associated with more complications, which contributed to a cost per live birth in anovulatory overweight and obese women 54 and 100% higher than in their normal weight counterparts, and in ovulatory overweight and obese women 44 and 70% higher.21 Strategies for weight reduction Weight reduction before natural or assisted conception is the best isolated measure to improve both fertility potential and pregnancy outcome in obese women. Such a measure would also reduce costs. Lifestyle modification, including reduced calorie intake, adapted physical exercise and psychological support with close monitoring from a multidisciplinary team seems the best and most effective way to achieve this goal. Pharmacotherapy may cause important and frequent side effects, with little weight loss and 31 sept13_nwp_50939 22/08/2013 13:04 Page 32 rapid re-gain after discontinuation. Bariatric surgery should be considered the last line therapy for weight reduction in the context of reproduction. Despite the fact that it currently constitutes the best option for a greater and longer sustainable weight reduction, it is associated with significant morbidity and non-negligible mortality and its effects on fertility, pregnancy and long-term outcome in the offspring are not yet really known. José Bellver is Associate Professor of Reproductive Medicine at the University of Valencia and at IVI Valencia, Spain. References 1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief 2012; 82: 1-8. 2. Lakshman R, Elks CE, Ong KK. Childhood obesity. Circulation 2012; 126: 1770-1779. 3. Polotsky AJ, Hailpern SM, Skurnick JH, et al. Association of adolescent obesity and lifetime nulliparity - the Study of Women’s Health Across the Nation (SWAN). Fertil Steril 2010; 93: 20042011. 4. Wise LA, Rothman KJ, Mikkelsen EM, et al. An internetbased prospective study of body size and time-to-pregnancy. Hum Reprod 2010; 25: 253-2564. 5. Van der Steeg JW, Steures P, Eijkemans MJ, et al. Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women. Hum Reprod 2008; 23: 324-328. 6. Ramlau-Hansen CH, Thulstrup AM, Nohr EA, et al. Subfecundity in overweight and obese couples. Hum Reprod 2007; 22: 1634-1637. 7. White DM, Polson DW, Kiddy D, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 1996; 81:3 821-824. 8. Al-Azemi M, Omu FE, Omu AE. The effect of obesity on the outcome of infertility management in women with polycystic ovary syndrome. Arch Gynecol Obstet 2004; 270: 205-210. 9. Zaadstra BM, Seidell JC, Van Noord PA, et al. Fat and female fecundity: prospective study of effect of body fat distribution on conception rates. BMJ 1993; 306: 484-4847. 10. Bellver J, Ayllón Y, Ferrando M, et al. Female obesity impairs in vitro fertilization outcome without affecting embryo quality. Fertil Steril 2010; 93: 447-454. 11. Rittenberg V, Seshadri S, Sunkara SK, et al. Effect of body mass index on IVF treatment outcome: an updated systematic review and meta-analysis. Reprod Biomed Online 2011; 23: 421-439. 12. Luke B, Brown MB, Stern JE, et al; SART Writing Group. Female obesity adversely affects assisted reproductive technology (ART) pregnancy and live birth rates. Hum Reprod 2011; 26: 245-252 13. Petersen GL, Schmidt L, Pinborg A, Kamper-Jorgensen M. The influence of female and male body mass index on livebirth rates after Assisted Reproductive Technology treatment – a nationwide register-based cohort study. Fertil Steril 2013, 99: 1654-1562. 14. Bellver J, Mifsud A, Grau N, et al. Embryos derived from obese or normoweight infertile women do not present a different morphokinetic pattern: a time-lapse study. Hum Reprod 2013; 28: 794-800. 15. Bellver J, Pellicer A, García-Velasco JA, et al. Obesity and impaired uterine receptivity: clinical experience from 9,587 first cycles of ovum donation. Oral communication. 29th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE). London 2013. Hum Reprod 2013; 28: S1 O-175 16. Bellver J, Martínez-Conejero JA, Labarta E, et al. Endometrial gene expression in the window of implantation is altered in obese women especially in association with polycystic ovary syndrome. Fertil Steril 2011; 95: 2335-2341. 17. Bellver J, Cruz F, Martínez MC, Ferro J, et al. Female overweight is not associated with a higher embryo euploidy rate in first trimester miscarriages karyotyped by hysteroembryoscopy. Fertil Steril 2011; 96: 931-933 18. Catalano PM. Management of obesity in pregnancy. Obstet Gynecol 2007; 109: 419-433. 19. Symonds ME, Sebert SP, Hyatt MA, Budge H. Nutritional programming of the metabolic syndrome. Nat Rev Endocrinol 2009; 5: 604-610. 20. Wang YC, McPherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378: 815-825. 21. Koning AM, Kuchenbecker WK, Groen H, et al. Economic consequences of overweight and obesity in infertility: a framework for evaluating the costs and outcomes of fertility care. Hum Reprod Update 2010; 16: 246-254. // TASK FORCE FERTILITY AND VIRAL DISEASES // More evidence on sperm washing in HIV couples A final follow-up paper on the three-step sperm washing technique developed in Italy in 1987 has now been published. Reproductive health clinics in Europe have since then offered sperm washing-IUI to HIV patients, reporting no transmission attributable to the procedure. Incomplete follow-up, however, has been a source of uncertainty in previous studies. Notwithstanding the existence of two large retrospective analyses of choices and practices among couples with HIV focusing on the efficacy of the procedure, 32 no study has previously given a definitive answer on the safety of the sperm washing method in HIV serodiscordant couples. This study now provides such confirmation. Enrico Semprini Co-ordinator Task Force Fertility and Viral Diseases Semprini AE, Macaluso M, Hollander L, et al. Safe conception for HIV-discordant couples: insemination with processed semen from the HIV-infected partner. Am J Obstet Gynecol 2013; 208: 402. Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:04 Page 33 LAST WORD Robert Edwards: the final respects Former ESHRE Chairman Luca Gianaroli records his own impressions from the funeral of Bob Edwards, while Basil Tarlatzis, anothert former ESHRE Chairman, reflects on the qualities of character on which ESHRE and its journals were built “ It is 25 years since I last left behind the huge lawns which surround Bourn Hall. Back then, I was sitting in an old taxi that was taking me to the railway station. Bob was on the doorstep waving goodbye. Today, I am on the back seat of an elegant sedan. But the doorstep behind is empty, and no one is saying goodbye. For this is also my return home from the funeral service of Professor Robert Edwards, someone to whom I owe most of the few things I know. It was extremely important to pay him my last respects, both personally and on behalf of the Society he founded almost 30 years ago. The Chapel at Churchill College, Cambridge, where Bob's funeral took place on 26th April, is a dramatic modern building surrounded by lush gardens and trees. Inside, there are many people I know, each one aware of how important this moment is. Everyone has been allocated a seat, each one labelled with the name of the guest. No one is left standing. I asked an old English friend, who formerly worked in Bob’s lab in Cambridge, why there was a two-week wait between Bob’s death and the funeral. Answer: there was a long waiting-list for cremation and Bob had to wait like all the others. The funeral service includes many tributes from friends, colleagues, children and grand-children. Each of them talks of happy moments spent with Bob. There are very few tears LUCA GIANAROLI: ‘BOB’S WORK WAS THE CATALYST WHICH BROUGHT US TOGETHER - IN SOME CASES TO BE GOOD FRIENDS’ Focus on Reproduction September 2013 and a lot of laughter. The tributes - mostly spoken, one played on an oboe - are interspersed with a selection of popular and operatic music and English hymns. For this is a service for the life of Bob Edwards, not merely a moment of mourning. After the service Bob is driven to Cambridge Crematorium for his final committall. Outside the chapel, in the sun-drenched gardens of this Spring day, friends and colleagues stop by to exchange a word, some meeting for the first time in many years. We talk about ourselves and how Bob’s work was the catalyst which brought us together - in some cases to become good friends. Driving to the crematorium, I think about the last words of one of the tributes . . . about something he never did during his career. For Bob never attempted to patent any of the techniques he developed during his career. They were always left as discoveries freely available to everyone . . . and I think how hard I had tried at times to patent some instrument or some minor procedure which might at best add no more than marginal improvement to the huge gift that he gave so generously to all of us. Only when the heavy green curtains of the crematorium close behind Bob’s coffin do I finally realise that those curtains are also closing a chapter in the life of so many people - and in particular my own.. Before stepping down from the podium, Bob’s daughter reminds us that at this moment there are so many other people who are also saying goodbye to a father. And it’s now, at this point, that I see one of Bob’s first co-workers (now a senior figure well know for his tough lectures) crying silently. Later still, Bourn Hall is more charming than I ever remember it. A wonderful English country house where time has stopped but the miracle of life goes on day after day. On a big screen, we see the images of Bob’s life. Fragments pass by in front of me . . . myself 20 or 30 years ago with Bob, Alan Trounson, Jacques Cohen, Kay 33 sept13_nwp_50939 22/08/2013 13:04 Page 34 Elder, Colin Howles, Bill Walters and so many more. Now, they are spread across the world, but today they are all here to celebrate the life of the one man who brought us together. What a wonderful life! So now, in the ever buoyant atmosphere of Bourn Hall, people talk about the future of IVF technology, about new developments and about the young talents emerging in our field, just as Bob would have wanted. So work as ever invades Bourn Hall, and brings a sunny almost unreal afternoon back down to earth. I stop before leaving because Ruth, Bob’s wife, stares at my surgical collar. I have recently had cervical spine surgery, and Ruth thanks me for coming. She never accompanied Bob to any of the scientific or social events to which Bob was so frequently invited all over the world and I remember the difficulties of trying to convince her to receive Bob's Nobel prize. I promise that I will send her a special memento of Bob that is special to me. And only now, as the car turns to follow the sweeping curve of the driveway and out through the Bourn Hall gates do I sense that this chapter of my life - indeed of all our lives - has finally closed: this is the only sad moment of the day. Luca Gianaroli ESHRE Chairman 2009-2011 Scientist, visionary, mentor and friend It has been almost 30 years since I first met Bob and I still remember him, the evening of 17th May 1984 in Hall B of Finlandia Hall, Helsinki, presenting his proposals for a European society devoted to the new field of human assisted reproduction. As always, he was enthusiastic, passionate and convincing. After all, that is how Bob was, irrespective of whether he was talking about ESHRE and its journals, about science or politics. That is what drove him and led many of us to support him. He was a real leader. And this is what ESHRE owes to him. It was these same qualities, together with his persistence, which gave him the strength to continue his work in human IVF, despite scientific difficulties, moral opposition and even insults. And remarkably, he was able to describe from a very early date all possible applications and implications of IVF - blastocyst transfer, oocyte donation, embryo cryopreservation, in vitro maturation, stem cells or reproductive cloning. At the same time, he fully appreciated the ethical implications of this new technology and he was the first to open discussion with the public. He never avoided this debate, always fighting for justice and equal reproductive rights. As a true mentor, Bob was always close not only to his students but also to his colleagues, especially the younger ones. He would listen carefully to their ideas, argue with them and propose possible explanations or alternative approaches. As the editor of the Human Reproduction journals, he read every single paper submitted, trying his best to identify its innovation and value. I remember him saying that his mission was to help young scientists, not to destroy them. I have no doubt that this attitude played a fundamental role in 34 the phenomenal success of the journals and in their high impact factors. Bob was a full and unique man: a superb scientist of the highest integrity, a visionary ready to fight for his ideas, scientific or political, without unnecessary compromises, and yet a humble and warm friend for many of us, with an unforgettable full-hearted laugh. He created a whole new scientific field of assisted conception, which changed the life of millions of couples and the careers of all of us, clinicians and scientists who, inspired by him, decided to follow his path. It gives me great pleasure that ESHRE, in recognition of his achievements and contribution to the Society, offered him honorary membership at the 1993 annual meeting in Thessaloniki, which was presented by André Van Steirteghem and me. I know it meant a lot to him and he will be remembered by all of us in ESHRE, grateful for his vision of a European society, and for the firm foundations he indisputably laid. Basil C. Tarlatzis ESHRE Chairman 1997-1999 BASIL TARLATZIS: ‘BOB WAS A FULL AND UNIQUE MAN, A SUPERB SCIENTIST OF THE HIGHEST INTEGRITY.’ Focus on Reproduction September 2013 sept13_nwp_50939 22/08/2013 13:04 Page 35 sept13_nwp_50939 22/08/2013 13:04 Page 36 The European Society of Human Reproduction and Embryology Meerstraat 60 Grimbergen, Belgium [email protected] www.eshre.eu
© Copyright 2024